<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">63545</article-id><article-id pub-id-type="doi">10.7554/eLife.63545</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Mutations in SKI in Shprintzen–Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-210136"><name><surname>Gori</surname><given-names>Ilaria</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1913-8520</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-98468"><name><surname>George</surname><given-names>Roger</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5547-337X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-186530"><name><surname>Purkiss</surname><given-names>Andrew G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5931-3509</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210137"><name><surname>Strohbuecker</surname><given-names>Stephanie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9781-6879</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210138"><name><surname>Randall</surname><given-names>Rebecca A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210139"><name><surname>Ogrodowicz</surname><given-names>Roksana</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210140"><name><surname>Carmignac</surname><given-names>Virginie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8802-6448</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-91460"><name><surname>Faivre</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-210141"><name><surname>Joshi</surname><given-names>Dhira</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8660-2528</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-113796"><name><surname>Kjær</surname><given-names>Svend</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9767-8683</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-54358"><name><surname>Hill</surname><given-names>Caroline S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8632-0480</contrib-id><email>caroline.hill@crick.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Developmental Signalling Laboratory, The Francis Crick Institute</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution>Structural Biology Facility, The Francis Crick Institute</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution>Bioinformatics and Biostatistics Facility, The Francis Crick Institute</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution>INSERM - Université de Bourgogne UMR1231 GAD, FHU-TRANSLAD</institution><addr-line><named-content content-type="city">Dijon</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution>Peptide Chemistry Facility, The Francis Crick Institute</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Cole</surname><given-names>Philip A</given-names></name><role>Senior Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewing Editor</role><aff><institution>University of Massachusetts Medical School</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>01</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e63545</elocation-id><history><date date-type="received" iso-8601-date="2020-09-28"><day>28</day><month>09</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-01-07"><day>07</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Gori et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Gori et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-63545-v2.pdf"/><abstract><p>Shprintzen–Goldberg syndrome (SGS) is a multisystemic connective tissue disorder, with considerable clinical overlap with Marfan and Loeys–Dietz syndromes. These syndromes have commonly been associated with enhanced TGF-β signaling. In SGS patients, heterozygous point mutations have been mapped to the transcriptional co-repressor SKI, which is a negative regulator of TGF-β signaling that is rapidly degraded upon ligand stimulation. The molecular consequences of these mutations, however, are not understood. Here we use a combination of structural biology, genome editing, and biochemistry to show that SGS mutations in SKI abolish its binding to phosphorylated SMAD2 and SMAD3. This results in stabilization of SKI and consequently attenuation of TGF-β responses, both in knockin cells expressing an SGS mutation and in fibroblasts from SGS patients. Thus, we reveal that SGS is associated with an attenuation of TGF-β-induced transcriptional responses, and not enhancement, which has important implications for other Marfan-related syndromes.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Shprintzen-Goldberg syndrome</kwd><kwd>SKI</kwd><kwd>TGF-β</kwd><kwd>Activin</kwd><kwd>SMAD</kwd><kwd>Marfan syndrome</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010438</institution-id><institution>Francis Crick Institute</institution></institution-wrap></funding-source><award-id>FC10095</award-id><principal-award-recipient><name><surname>Gori</surname><given-names>Ilaria</given-names></name><name><surname>George</surname><given-names>Roger</given-names></name><name><surname>Purkiss</surname><given-names>Andrew G</given-names></name><name><surname>Strohbuecker</surname><given-names>Stephanie</given-names></name><name><surname>Randall</surname><given-names>Rebecca A</given-names></name><name><surname>Ogrodowicz</surname><given-names>Roksana</given-names></name><name><surname>Joshi</surname><given-names>Dhira</given-names></name><name><surname>Kjaer</surname><given-names>Svend</given-names></name><name><surname>Hill</surname><given-names>Caroline S</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The mechanism underlying Shprintzen–Goldberg syndrome is solved and reveals that missense mutations in the transcriptional repressor SKI abolish ligand-induced SKI degradation, which results in attenuation of TGF-β transcriptional responses.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Shprintzen–Goldberg syndrome (SGS) is a multisystemic connective tissue disorder. Common features observed in SGS patients include craniofacial, skeletal, and cardiovascular anomalies, ranging from heart valve defects to thoracic aortic aneurysms, all of which are also characteristic of Marfan syndrome (MFS) and Loeys–Dietz syndrome (LDS) (<xref ref-type="bibr" rid="bib10">Cook et al., 2015a</xref>; <xref ref-type="bibr" rid="bib78">Verstraeten et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Loeys et al., 2005</xref>; <xref ref-type="bibr" rid="bib81">Williams et al., 2007</xref>). In addition, SGS patients present with craniosynostosis, intellectual disability, and skeletal muscle hypotonia (<xref ref-type="bibr" rid="bib71">Shprintzen and Goldberg, 1982</xref>; <xref ref-type="bibr" rid="bib23">Glesby and Pyeritz, 1989</xref>; <xref ref-type="bibr" rid="bib24">Greally et al., 1998</xref>). All three syndromes have been linked to deregulation of the transforming growth factor β (TGF-β) signaling pathway (<xref ref-type="bibr" rid="bib6">Cannaerts et al., 2015</xref>).</p><p>The TGF-β family of ligands comprises the TGF-βs themselves, Activins, Nodal, bone morphogenetic proteins (BMPs), and growth differentiation factors (GDFs) and they play pleiotropic roles in embryonic development and tissue homeostasis. In addition, their signaling is deregulated in diverse pathologies (<xref ref-type="bibr" rid="bib49">Miller and Hill, 2016</xref>). They exert their action by binding to type I and type II serine/threonine kinase receptors at the cell surface (TGFBR1 and TGFBR2, respectively, for the TGF-βs) (<xref ref-type="bibr" rid="bib46">Massagué, 2012</xref>). In the resulting ligand-bound heterotetrameric receptor complex, the type II receptor phosphorylates and activates the type I receptor, which in turn phosphorylates the intracellular mediators, the receptor-regulated SMADs (R-SMADs). Once phosphorylated, the R-SMADs (SMAD2 and SMAD3 in the case of TGF-β, Activin, and Nodal) associate with the common mediator of the pathway, SMAD4. The resulting heterotrimeric complexes accumulate in the nucleus where they interact with other transcriptional regulators to activate or repress target gene expression (<xref ref-type="bibr" rid="bib46">Massagué, 2012</xref>). Two highly related co-repressors, SKI and SKIL (formerly known as SnoN), act as negative regulators in the pathway (<xref ref-type="bibr" rid="bib14">Deheuninck and Luo, 2009</xref>; see below).</p><p>The role of deregulated TGF-β signaling in Marfan-related syndromes is controversial. MFS is caused by loss-of-function mutations in the extracellular matrix protein, Fibrillin 1 (FBN1) (<xref ref-type="bibr" rid="bib16">Dietz et al., 1991</xref>). These mutations are thought to increase the bioavailability of TGF-β ligands, as FBN1 binds the latent form of the TGF-βs (<xref ref-type="bibr" rid="bib54">Neptune et al., 2003</xref>; <xref ref-type="bibr" rid="bib32">Kaartinen and Warburton, 2003</xref>). Supporting the idea that excessive TGF-β signaling contributes to the manifestations of MFS, a TGF-β neutralizing antibody significantly improved the lung phenotype in a mouse model of MFS (homozygous Fbn1<sup>mgΔ</sup>) (<xref ref-type="bibr" rid="bib54">Neptune et al., 2003</xref>; <xref ref-type="bibr" rid="bib6">Cannaerts et al., 2015</xref>) and reduced the occurrence of aortic aneurysms in the Fbn1<sup>C1039G/+</sup> mouse model of MFS (<xref ref-type="bibr" rid="bib27">Habashi et al., 2006</xref>). Contradicting these results, others have shown that the aortopathy in the Fbn1<sup>C1039G/+</sup> mouse model is not mediated by excessive TGF-β signaling and in fact is exacerbated by loss of TGF-β signaling in smooth muscle cells (<xref ref-type="bibr" rid="bib80">Wei et al., 2017</xref>). Furthermore, TGF-β signaling protects against abdominal aortic aneurysms in angiotensin II-infused mice (<xref ref-type="bibr" rid="bib3">Angelov et al., 2017</xref>). This controversy emphasizes the importance of understanding exactly how TGF-β signaling is impacted in MFS. Furthermore, the related syndrome LDS is caused by pathogenic mutations in several different components of the TGF-β pathway, TGFBR1, TGFBR2, SMAD2, SMAD3, and the ligands, TGFB2 and TGFB3. These mutations all cause missense amino acid substitutions that have been either verified in vitro, or are predicted to be loss of function, implying that LDS is caused by attenuated TGF-β signaling (<xref ref-type="bibr" rid="bib29">Horbelt et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Cardoso et al., 2012</xref>; <xref ref-type="bibr" rid="bib69">Schepers et al., 2018</xref>). However, paradoxically, histological and biochemical studies of aortic tissue derived from LDS patients reveal an apparent high TGF-β signaling signature (<xref ref-type="bibr" rid="bib77">van de Laar et al., 2012</xref>; <xref ref-type="bibr" rid="bib22">Gallo et al., 2014</xref>; <xref ref-type="bibr" rid="bib39">Lindsay et al., 2012</xref>). SGS is caused by mutations in SKI, and both SMAD-mediated and non-SMAD-mediated TGF-β signaling has been reported to be increased in primary dermal fibroblasts from SGS patients (<xref ref-type="bibr" rid="bib19">Doyle et al., 2012</xref>).</p><p>The co-repressors SKI and SKIL play important roles in a number of different cellular processes including proliferation, differentiation, transformation, and tumor progression (<xref ref-type="bibr" rid="bib4">Bonnon and Atanasoski, 2012</xref>). They are dimeric proteins that interact with both phosphorylated SMAD2 and SMAD3 (PSMAD2 or PSMAD3) via short motifs at their N-termini, and with SMAD4 via a SAND domain (named after Sp100, AIRE-1, NucP41/75, DEAF-1) in the middle of both proteins (<xref ref-type="bibr" rid="bib14">Deheuninck and Luo, 2009</xref>). Between these two domains lies a Dachshund homology domain (DHD), which is thought to also be important for R-SMAD binding (<xref ref-type="bibr" rid="bib82">Wilson et al., 2004</xref>; <xref ref-type="bibr" rid="bib76">Ueki and Hayman, 2003</xref>). SKI and SKIL both contain a leucine zipper domain in their C-termini, through which they dimerize (<xref ref-type="bibr" rid="bib14">Deheuninck and Luo, 2009</xref>). They are negative regulators of TGF-β/Activin signaling, with two distinct mechanisms of regulation having been proposed. In one model, SKI and SKIL bind with SMAD4 to SMAD binding elements (SBEs) of TGF-β/Activin target genes, and recruit co-repressors such as NCOR1 or SIN3A (<xref ref-type="bibr" rid="bib75">Tokitou et al., 1999</xref>; <xref ref-type="bibr" rid="bib56">Nomura et al., 1999</xref>; <xref ref-type="bibr" rid="bib73">Stroschein et al., 1999</xref>; <xref ref-type="bibr" rid="bib14">Deheuninck and Luo, 2009</xref>). They thus maintain the transcription of these target genes suppressed in the absence of signal. Upon TGF-β/Activin signaling, SKI and SKIL are rapidly degraded by the E3 ubiquitin ligase, RNF111 (formerly known as Arkadia), a process that requires SKI/SKIL binding to PSMAD2 or PSMAD3 (<xref ref-type="bibr" rid="bib35">Le Scolan et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>; <xref ref-type="bibr" rid="bib53">Nagano et al., 2007</xref>). This then allows the activated SMAD3–SMAD4 complexes to bind the exposed SBEs and activate target gene transcription (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>; <xref ref-type="bibr" rid="bib73">Stroschein et al., 1999</xref>). In the competing model, SKI and SKIL act as repressors of active signaling simply by binding to PSMAD2 or PSMAD3 and SMAD4 in such a way as to disrupt the activated PSMAD2/PSMAD3–SMAD4 complexes (<xref ref-type="bibr" rid="bib43">Luo, 2004</xref>; <xref ref-type="bibr" rid="bib76">Ueki and Hayman, 2003</xref>; <xref ref-type="bibr" rid="bib88">Wu et al., 2002</xref>). The heterozygous missense mutations that cause SGS have been mapped in SKI to the N-terminal R-SMAD-binding domain, with some small deletions and point mutations also found in the DHD, which is also necessary for R-SMAD binding (<xref ref-type="bibr" rid="bib8">Carmignac et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Doyle et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Schepers et al., 2015</xref>). Thus, depending on the mechanism whereby SKI inhibits TGF-β/Activin signaling, loss of the interaction with PSMAD2/PSMAD3 would be predicted to have opposite effects on signaling output. If the PSMAD2/PSMAD3 interaction is required for SKI degradation, its loss would inhibit TGF-β signaling. However, if SKI binding to PSMAD2/PSMAD3 disrupts active SMAD complexes, then its loss would promote TGF-β signaling.</p><p>Here we use a combination of genome editing, structural biology, biochemistry, and analysis of patient samples to elucidate the molecular mechanism underlying SGS and to resolve the paradox surrounding the role of TGF-β signaling in Marfan-related syndromes. We first determine at the molecular level how SKI/SKIL function in the TGF-β/Activin signaling pathways and show that an intact ternary phosphorylated R-SMAD–SMAD4 complex is required for ligand-induced SKI/SKIL degradation. We demonstrate that the SGS mutations in SKI abolish interaction with PSMAD2 and PSMAD3 and this results in an inability of SKI to be degraded in response to TGF-β/Activin signaling. We go on to show that SKI stabilization results in an attenuation of the TGF-β transcriptional response in both knockin HEK293T cells and fibroblasts from SGS patients. Our work unequivocally establishes that SGS mutations lead to an attenuated TGF-β response, which has major implications for all the Marfan-related syndromes.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A PSMAD2/3–SMAD4 ternary complex is essential for TGF-β/Activin-induced degradation of SKI/SKIL</title><p>To understand the consequences of SKI mutations in SGS and to resolve the paradox surrounding the function of TGF-β signaling in Marfan-related syndromes, we first set out to determine exactly how SKI and SKIL act as negative regulators of TGF-β and Activin signaling. We and others have previously demonstrated that SKI and SKIL are rapidly degraded upon TGF-β/Activin stimulation by the E3 ubiquitin ligase RNF111, and this requires PSMAD2 or PSMAD3 (<xref ref-type="bibr" rid="bib35">Le Scolan et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>; <xref ref-type="bibr" rid="bib53">Nagano et al., 2007</xref>). Knockdown experiments suggested that SMAD4 was not necessary (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>), but we subsequently showed that tumor cells deleted for SMAD4 or containing mutations in SMAD4 that abolish interactions with activated R-SMADs, abrogated TGF-β-induced degradation of SKI/SKIL (<xref ref-type="bibr" rid="bib5">Briones-Orta et al., 2013</xref>). Whether the requirement for SMAD4 was direct or indirect was not clear.</p><p>To define the role of SMAD4 in SKI/SKIL degradation, we used CRISPR/Cas9 technology to delete SMAD4 in transformed embryonic kidney cells HEK293T, which express both SKI and SKIL, and in the human keratinocyte cell line, HaCaT, which predominantly express SKIL (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>; <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). In wild-type (WT) cells, TGF-β/Activin induced rapid SKI and SKIL degradation, compared to cells treated with the TGFBR1 inhibitor, SB-431542 (<xref ref-type="bibr" rid="bib30">Inman et al., 2002</xref>; <xref ref-type="fig" rid="fig1">Figure 1A,B</xref>). Deletion of SMAD4 in multiple clones of both cell types abolished ligand-induced SKI/SKIL degradation (<xref ref-type="fig" rid="fig1">Figure 1A,B</xref>). We validated these SMAD4-null cell lines by demonstrating that transient expression of SMAD4 could rescue TGF-β/Activin-induction of the SMAD3–SMAD4 reporter, CAGA<sub>12</sub>-Luciferase (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). Furthermore, we could show that loss of SMAD4 inhibited the ligand-induced expression of a number of endogenous TGF-β and BMP target genes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). By knocking out SMAD2 or SMAD3 individually or together, we also confirmed that these R-SMADs are absolutely required for TGF-β/Activin-induced degradation of SKI and SKIL and act redundantly (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Thus, R-SMADs and SMAD4 are all essential for TGF-β/Activin-dependent SKI/SKIL degradation.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Requirement of SMAD2 or SMAD3 and SMAD4 for SKI and SKIL degradation.</title><p>(<bold>A and C</bold>) The parental HEK293T cell line and two individual SMAD4 knockout clones (<bold>A</bold>) or two individual SMAD2, SMAD3 knockout clones, or two SMAD2 and SMAD3 double knockout clones (<bold>C</bold>) were incubated overnight with 10 μM SB-431542, washed out, then incubated with full media containing either SB-431542 or 20 ng/ml Activin A for 1 hr, as indicated. Whole-cell extracts were immunoblotted with the antibodies indicated. (<bold>B</bold>) Parental HaCaT and four individual SMAD4 knockout clones were treated as above, except that they were treated with 2 ng/ml TGF-β for 1 hr instead of Activin A. Nuclear lysates were immunoblotted using the antibodies indicated. SB, SB-431542; A, Activin A; T, TGF-β; S2, SMAD2; S3, SMAD3; S2/3, SMAD2 and SMAD3; S4, SMAD4; KO, knockout; dKO, double knockout.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Sequences of knockout alleles made in HEK293T cells.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-63545-fig1-data1-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>SMAD4 is essential for TGF-β/Activin-induced transcriptional responses.</title><p>(<bold>A and B</bold>) HEK293T (<bold>A</bold>) or HaCaT (<bold>B</bold>) parental cells and individual clones of SMAD4 knockout cells were transiently transfected with CAGA<sub>12</sub>-Luciferase together with TK-Renilla as an internal control and a plasmid expressing human SMAD4 as indicated (<bold>A and B</bold>). Cells were incubated with 0.5% fetal bovine serum-containing media overnight and then treated with 20 ng/ml Activin (<bold>A</bold>) or 2 ng/ml TGF-β (<bold>B</bold>) for 8 hr. Cell lysates were prepared and Luciferase/Renilla activity was measured. Plotted are the means ± SEM of three independent experiments. The p-values are from one-way ANOVA with Tukey’s post hoc correction. *p&lt;0.05; ***p&lt;0.001; ****p&lt;0.0001. (<bold>C</bold>) HaCaT parental and four independent clones of SMAD4 knockout cells were either untreated or incubated with either 2 ng/ml TGF-β or 20 ng/ml BMP4 for 1 hr (<italic>SMAD7</italic>, <italic>JUNB</italic>, <italic>ID1</italic>, and <italic>ID3</italic>) or 6 hr (<italic>SERPINE1</italic> and <italic>SKIL</italic>). Total RNA was extracted and qPCR was used to assess the levels of mRNA for the genes shown. The data are the average of three or four experiments ± SEM. The p-values are from one-way ANOVA with Tukey’s post hoc correction. **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. Par, parental; S4 KO, SMAD4 knockout.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Luciferase assay data for HEK293T S4 KO clones, as presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Luciferase assay data for HaCaT S4 KO clones, as presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig1-figsupp1-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>qPCR data for HaCaT S4 KO clones, as presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig1-figsupp1-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig1-figsupp1-v2.tif"/></fig></fig-group><p>In addition to forming a ternary complex with PSMAD2 or PSMAD3, SMAD4 has also been shown to interact directly with SKI and SKIL through their SAND domains (<xref ref-type="bibr" rid="bib79">Walldén et al., 2017</xref>; <xref ref-type="bibr" rid="bib88">Wu et al., 2002</xref>). To determine which of these SMAD4 interactions were important for TGF-β/Activin-induced SKI/SKIL degradation, we stably reintroduced enhanced GFP (EGFP) fusions of WT or mutated SMAD4 into HaCaT SMAD4-null cells. We selected two missense mutations on opposite faces of the C-terminal Mad homology 2 (MH2) domain of SMAD4: Asp351-&gt;His (D351H) and Asp537--&gt;Tyr (D537Y) (<xref ref-type="bibr" rid="bib70">Shi et al., 1997</xref>). These have been shown to occur naturally in the human colorectal cancer cell lines CACO-2 and SW948, and have lost the ability to bind phosphorylated R-SMADs (<xref ref-type="bibr" rid="bib13">De Bosscher et al., 2004</xref>). In addition, we used the crystal structure of the MH2 domain of SMAD4 and the SAND domain of SKI, to design two mutations Ala433--&gt;Glu (A433E) and Ile435--&gt;Tyr (I435Y), that would be expected to abolish SMAD4 binding to SKI and SKIL (<xref ref-type="bibr" rid="bib88">Wu et al., 2002</xref>).</p><p>We confirmed that these SMAD4 mutants behaved as expected in the rescue cell lines by testing their interaction with SKIL and R-SMADs by immunoprecipitation. As endogenous RNF111 triggers SKIL degradation in TGF-β/Activin-dependent manner, the stable SMAD4-expressing HaCaT rescue cell lines were incubated with the proteasome inhibitor, MG-132 for 3 hr prior to TGF-β stimulation, to block SKIL degradation. As predicted, the D351H and D537Y SMAD4 mutants had lost their ability to bind SMAD2 upon TGF-β induction, but retained the interaction with SKIL. By contrast, A433E and I435Y SMAD4 mutants were unable to bind SKIL, but could interact with SMAD2 upon TGF-β stimulation (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Furthermore, as expected, D351H and D537Y SMAD4 mutants failed to rescue the ability of TGF-β to induce expression of CAGA<sub>12</sub>-Luciferase in HaCaT SMAD4-null cells or rescue TGF-β-induced transcription of target genes, but the A433E and I435Y SMAD4 mutants rescued these responses almost as well as WT SMAD4 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Characterization of the role of SMAD4 in TGF-β-induced SKIL degradation.</title><p>(<bold>A–C</bold>) HaCaT SMAD4 knockout (S4 KO) cells were stably transfected with EGFP alone, or EGFP SMAD4 (WT) or with four different EGFP-SMAD4 mutants (D351H, D537Y, which abolish interaction with the R-SMADs, and A433E and I435Y, which do not interact with SKIL). (<bold>A</bold>) Cells were incubated overnight with 10 µM SB-431542, washed out and pre-incubated with 25 μM MG-132 for 3 hr, and then treated either with 10 μM SB-431542 or 2 ng/ml TGF-β for 1 hr. Whole-cell extracts were immunoprecipitated (IP) with GFP-trap agarose beads. The IPs were immunoblotted using the antibodies shown. Inputs are shown below. (<bold>B</bold>) Nuclear lysates were prepared from the HaCaT S4 KO cells stably transfected with EGFP alone or with EGFP-SMAD4 constructs as indicated, treated as in (<bold>A</bold>), but without the MG-132 step and immunoblotted using the antibodies shown. On the right the quantifications are the normalized average ± SEM of five independent experiments. The quantifications are expressed as fold changes relative to SB-431542-treated S4 KO cells. (<bold>C</bold>) Levels of SKIL in the EGFP-positive S4 KO rescue cell lines treated as in (<bold>B</bold>), assayed by flow cytometry. Each panel shows an overlay of the indicated treatment conditions. The red line indicates the SB-431542-treated sample, whereas the cyan line indicates the TGF-β-treated sample. Quantifications are shown bottom right. For each group, the percentage of the median fluorescence intensity normalized to the SB-431542-treated sample is quantified. Data are the mean ± SEM of five independent experiments. The p-values are from one-way ANOVA with Sidak’s post hoc correction *p&lt;0.05; ****p&lt;0.0001. SB, SB-431542; T, TGF-β.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Quantification of Western blot for HaCaT S4 KO rescue cell lines, as presented in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig2-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Flow cytometry data for HaCaT S4 KO rescue cell lines, as presented in <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig2-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Transcriptional activity of the SMAD4 mutants compared to WT SMAD4.</title><p>(<bold>A</bold>) Parental HaCaT, SMAD4 knockout clone 2 stably transfected with EGFP alone (S4 KO), or with EGFP fusions of WT SMAD4 or the four indicated SMAD4 mutants were transiently transfected with CAGA<sub>12</sub>-Luciferase together with TK-Renilla as an internal control. Cells were untreated or treated with 2 ng/ml TGF-β for 8 hr. Luciferase/Renilla activity was measured on whole-cell lysates. Plotted are the means ± SEM of four independent experiments. The p-values are from one-way ANOVA with Tukey’s post hoc correction. ****p&lt;0.0001. (<bold>B</bold>) Parental HaCaT and SMAD4 knockout clone 2 cells stably transfected as in (<bold>A</bold>) were incubated overnight with 10 μM SB-431542, washed out, and then retreated with SB-431542 (SB) or with 2 ng/ml TGF-β (T) for 6 hr. Total RNA was extracted and qPCR was performed for the genes shown. Plotted are the means ± SEM of four independent experiments. The p-values are from two-way ANOVA with Sidak’s post hoc test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. (<bold>C</bold>) Levels of SKIL in parental HaCaT cells were measured by flow cytometry 1 hr after incubation with 10 μM SB-431542 or after treatment for 1 hr with 2 ng/ml TGF-β. The panel shows an overlay of the indicated treatment conditions. The red line indicates the SB-431542-treated sample, while the cyan line represents the TGF-β-treated sample.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Luciferase assay data for HaCaT S4 KO rescue cell lines, as presented in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>qPCR data for HaCaT S4 KO rescue cell lines, as presented in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig2-figsupp1-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig2-figsupp1-v2.tif"/></fig></fig-group><p>Having demonstrated that these mutants behaved as designed, we asked which were able to mediate TGF-β-induced SKIL degradation, using three different assays. In a Western blot assay using nuclear extract, we found that reintroduction of WT SMAD4 in SMAD4-null cells caused a 50% reduction in SKIL levels in TGF-β-induced cells compared to those treated with SB-431542 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). However, none of the four SMAD4 mutants could rescue TGF-β-induced SKIL degradation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). We then established a flow cytometry assay to quantify SKIL protein stability in EGFP/EGFP-SMAD4-expressing cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Treatment with TGF-β for 1 hr caused a 52% reduction in the relative median fluorescence intensity in the EGFP-SMAD4 WT-expressing cells, reflecting SKIL levels, compared to cells treated with SB-431542 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). However, for all four SMAD4 mutants tested, the median fluorescence was not decreased by TGF-β treatment (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Finally, we used an immunofluorescence analysis to monitor SKIL protein stability following TGF-β exposure. SMAD4-null cells showed strong nuclear staining of SKIL in the non-signaling condition (SB-431542), which remained unchanged by TGF-β treatment (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Reintroduction of WT EGFP-SMAD4 conferred the ability to degrade SKIL upon TGF-β treatment, whereas none of the mutant SMAD4s were able to rescue SKIL degradation (<xref ref-type="fig" rid="fig3">Figure 3</xref>, arrows). Thus, all three assays demonstrate that a ternary R-SMAD–SMAD4 complex is absolutely necessary for TGF-β-induced SKIL degradation, as is the ability of SMAD4 to interact with SKIL itself. This suggests that within a canonical activated ternary SMAD complex, the R-SMAD component binds to the N-terminal region of SKIL/SKI, whilst SMAD4 binds the SAND domain, and both interactions are absolutely required for SKIL/SKI degradation.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Visualization of TGF-β-induced SKIL degradation.</title><p>HaCaT SMAD4 knockout (S4 KO) cells or those stably expressing EGFP SMAD4 WT or EGFP SMAD4 mutants were incubated overnight with 10 μM SB-431542, washed out, and incubated for 1 hr with 10 µM SB-431542 or with 2 ng/ml TGF-β. Cells were fixed and stained for EGFP (for SMAD4), SKIL, and with DAPI (blue) to mark nuclei and imaged by confocal microscopy. The merge combines SKIL, SMAD4, and DAPI staining. Arrows indicate examples of EGFP-expressing cells and corresponding levels of nuclear SKIL. Scale bar corresponds to 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig3-v2.tif"/></fig></sec><sec id="s2-2"><title>SGS mutations inhibit the interaction of SKI with phosphorylated R-SMADs</title><p>We next investigated the consequences of the SGS mutations on SKI and SKIL’s ability to interact with the R-SMADs. SKI and SKIL share a highly conserved region at their N-terminus comprising the domain known to be important for R-SMAD binding (<xref ref-type="bibr" rid="bib14">Deheuninck and Luo, 2009</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). We first determined the minimal region of SKI required for R-SMAD binding using peptide pulldown assays with biotinylated SKI peptides and whole-cell extract from uninduced and TGF-β-treated HaCaT cells. This revealed that amino acids 11–45 of SKI are sufficient for binding to PSMAD2 and PSMAD3 upon TGF-β stimulation, whilst the unphosphorylated SMADs did not bind to any of the SKI peptides (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). SMAD4 is also pulled down in these assays in a ligand-induced manner, by virtue of its interaction with the phosphorylated R-SMADs.</p><p>The SGS mutations discovered so far mostly cluster within this 11–45 region of SKI and a few deletions and point mutations have additionally been mapped in the DHD domain (<xref ref-type="bibr" rid="bib8">Carmignac et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Doyle et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Schepers et al., 2015</xref>). The residues mutated are completely conserved, both between species, and also in the related protein, SKIL (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib8">Carmignac et al., 2012</xref>). To determine the effect of these mutations on R-SMAD interaction, we introduced six different SGS mutations into the SKI peptide 11–45 and showed that they all prevented binding of PSMAD2 and PSMAD3, and as a result, also SMAD4 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). These results were also confirmed with the equivalent mutations in SKIL (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We proved that the interaction with SMAD2 was mediated via its MH2 domain using a mouse embryonic fibroblast cell line that expresses a truncated SMAD2 protein comprising just the MH2 domain (<xref ref-type="bibr" rid="bib57">Piek et al., 2001</xref>; <xref ref-type="bibr" rid="bib12">Das et al., 2009</xref>; <xref ref-type="fig" rid="fig4">Figure 4C</xref>). We confirmed this using recombinant human phosphorylated SMAD2 MH2 domain produced in insect cells by co-expressing the SMAD2 MH2 domain with the kinase domain of TGFBR1 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). In both cases, the SGS mutations prevented interaction of the SKI peptide with the SMAD2 MH2 domain.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>SGS mutations inhibit binding of SKI to SMAD2/3.</title><p>(<bold>A and B</bold>) HaCaT cells were treated or not with 2 ng/ml TGF-β. A peptide pulldown assay was performed on whole cells extracts and pulldowns were immunoblotted with the antibodies indicated. Inputs are shown on the right. (<bold>A</bold>) Wild-type (WT) SKI peptides corresponding to amino acids 11–45 or containing SGS point mutations as shown in red were used. (<bold>B</bold>) WT SKIL peptides corresponding amino acids 80–120 or containing mutations (in red) corresponding to SGS mutations in SKI were used. (<bold>C</bold>) WT SKI peptides or those containing SGS point mutations were used in pulldown assays with whole-cell extracts of SMAD2-null mouse embryonic fibroblasts that express just the MH2 domain of SMAD2 (MEF SMAD2<sup>Δex2</sup>) (<xref ref-type="bibr" rid="bib12">Das et al., 2009</xref>), treated with 2 ng/ml TGF-β. The untreated sample is only shown for the WT SKI peptide. A PSMAD2 immunoblot is shown. (<bold>D</bold>) A recombinant trimer of phosphorylated SMAD2 MH2 domain was used in a peptide pulldown assay with WT and G34D SKI peptides. A PSMAD2 immunoblot is shown, with inputs on the right. (<bold>E</bold>) Mutational peptide array of SKI peptides (amino acids 11–45), mutated at all residues between amino acids 19 and 35, was probed with a recombinant PSMAD3–SMAD4 complex, which was visualized using a SMAD2/3 antibody conjugated to Alexa 488. On each row, the indicated amino acid is substituted for every other amino acid. A representative example is shown. See <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref> and <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref> for quantification of the peptide arrays.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Peptide sequences for peptide array.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-63545-fig4-data1-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Quantification of peptide arrays.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig4-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>SGS mutations in SKI.</title><p>(<bold>A</bold>) Alignment of the first 317 amino acids of human SKI with the corresponding regions of mouse SKI and human SKIL is shown. Key domains are shown: pink corresponds to the R-SMAD-binding domain; blue, DHD domain; purple, SAND domain. SGS mutations are indicated by arrows. (<bold>B</bold>) SKI peptides corresponding to amino acids 11–51 and truncated versions as shown were analyzed in peptide pulldown assays with whole cell extracts from HaCaT cells treated with or without 2 ng/ml TGF-β. The pulldowns were immunoblotted using the antibodies shown. Inputs are shown on the right. (<bold>C</bold>) Quantification of the mutational peptide array of SKI peptides (amino acids 11–45), a representative of which is shown in <xref ref-type="fig" rid="fig4">Figure 4E</xref>. Each intensity measure is normalized to the average intensity of 60 positive controls of the WT peptide after subtracting the background, measured from the average intensity of 60 negative controls (truncated SKI peptide C as indicated in <bold>B</bold>). The values shown are the mean normalized intensities for each mutated peptide. See also <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig4-figsupp1-v2.tif"/></fig></fig-group><p>We next used a peptide array to gain a better understanding of which amino acids can be tolerated at the positions found to be mutated in SGS and to determine which other amino acids in this region of SKI are essential for the R-SMAD interaction. The SKI peptide corresponding to amino acids 11–45 was synthesized as an array on a cellulose sheet such that each residue in the sequence between residues 19 and 35 was substituted with all 19 alternative amino acids (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). The array was probed with a recombinant PSMAD3–SMAD4 trimer, generated by co-expressing SMAD3 and SMAD4 with the TGFBR1 kinase domain in insect cells. The PSMAD3–SMAD4 complex was then detected using a fluorescently-labeled SMAD2/3 antibody. Eight residues are intolerant to almost any amino acid substitution (Thr20, Leu21, Phe24, Ser28, Ser31, Leu32, Gly34, and Pro35). Strikingly, six of these residues are the amino acids known to be mutated in SGS patients, and the array results readily explain why these residues are mutated to a number of different amino acids in SGS (<xref ref-type="fig" rid="fig4">Figure 4E</xref>; for quantification, see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref> and <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>). In addition, Thr20 and Phe24 are also crucial residues for binding the PSMAD3–SMAD4 complex, but have not yet been reported as disease mutations. Mutations in the other nine amino acids do not impair the binding, and almost any other amino acid apart from proline can be tolerated at these positions.</p></sec><sec id="s2-3"><title>Crystal structure of the SKI peptide with the phosphorylated SMAD2 MH2 domain</title><p>To discover why these eight amino acids were so crucial for R-SMAD binding, and also to understand why SKI and SKIL only recognize phosphorylated R-SMADs, we solved the crystal structure of the SKI peptide (amino acids 11–45) with a phosphorylated homotrimer of the SMAD2 MH2 domain, produced in insect cells as described above. We confirmed using SEC-MALLS that the phosphorylated SMAD2 MH2 domain was indeed trimeric in solution (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Analysis of the binding affinity of the SKI peptide to the SMAD2 MH2 domain trimer indicated that the dissociation constant (<italic>K</italic><sub>d</sub>) was in the low nanomolar range (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). The structure was determined by molecular replacement and refined at 2 Å resolution and readily explained why the crucial amino acids identified in the peptide were required for SMAD2 binding (<xref ref-type="fig" rid="fig5">Figure 5</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Crystal structure of PSMAD2 MH2 domain and N-terminal SKI peptide.</title><p>(<bold>A</bold>) Crystal structure of the phosphorylated SMAD2 MH2 domain trimer (the three monomers are shown in bright green, cyan, and olive) with the N-terminal SKI peptide amino acids 11–45 (magenta). A ribbon representation is shown. The C-terminal phosphates are indicated with a ball and stick representation (red and magenta). (<bold>B–F</bold>) Close ups on key residues for SKI binding. SKI residues are shown in magenta, and SMAD2 residues are in green. In (<bold>B–D</bold>), a ribbon representation is shown. In (<bold>E and F</bold>), SMAD2 is shown as a surface representation and SKI as a ribbon. (<bold>G</bold>) A detail from the structure of monomeric SMAD2 MH2 domain with a peptide from ZFYVE9 (formerly called SARA) (<xref ref-type="bibr" rid="bib86">Wu et al., 2000</xref>). Note that the β1’ strand that contains Tyr268 is locked in a hydrophobic pocket, forcing Trp448 into flattened orientation, incompatible with SKI binding. (<bold>H</bold>) A detail from the structure in (<bold>A</bold>) indicating how SMAD2 complex formation shifts the position of the β1’ strand and more particularly, Tyr268, allowing Trp448 to flip 90°, enabling it to stack with SKI residues Phe24 and Pro35.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Structure validation report for crystal structure (ID: 6ZVQ).</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-63545-fig5-data1-v2.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Analysis of the phosphorylated SMAD2 MH2 domain complex used for structural studies.</title><p>(<bold>A</bold>) The trimeric arrangement of the phosphorylated SMAD2 MH2 domain was confirmed by SEC-MALLS. The SEC-MALLS chromatogram is shown. The calculated molecular weight was 81 kDa, which was very close to the expected molecular weight of 78.5 kDa. (<bold>B</bold>) The interaction between the phosphorylated SMAD2 MH2 domain and the SKI peptide (amino acids 11–45) was measured by biolayer interferometry. The biosensors were loaded with biotinylated SKI peptide and incubated with different concentrations of phosphorylated SMAD2 MH2 domain as shown. The calculated <italic>K</italic><sub>d</sub> was 1.33 × 10<sup>−9</sup> ± 2.12 x10<sup>−11</sup> M. (<bold>C</bold>) Data collection and refinement statistics for the crystal structure of the phosphorylated SMAD2 MH2 domain complex with the N-terminal region of SKI shown in <xref ref-type="fig" rid="fig5">Figure 5A</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig5-figsupp1-v2.tif"/></fig></fig-group><p>The SKI peptide binds on the outside face of the MH2 domain at the so-called three helix bundle, comprising helices 3, 4, and 5 (<xref ref-type="bibr" rid="bib87">Wu et al., 2001</xref>; <xref ref-type="fig" rid="fig5">Figure 5A</xref>). The N-terminal helix of SKI packs against helix 3 of SMAD2, and the C-terminal portion of the SKI peptide, which contains the critical Gly34 and Pro35, forms a sharp turn that is stabilized by pi-stacking coordination between Phe24 of SKI, Trp448 of SMAD2, and Pro35 of SKI (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Moreover, the NE1 of the Trp448 side chain forms a H-bond to the main chain carbonyl group of Gly33, which in turn positions Pro35 for the interaction with Trp448 (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Furthermore, Glu270 in SMAD2 provides a pocket, which has a negatively charged base that ties down SKI Gly34 through hydrogen-bonding to its main chain amides. Other key interactions involving amino acids identified above as crucial for binding include the main chain carbonyl of Ser31, which forms a hydrogen bond to the ND1 of Asn387 in helix 3 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), and the hydroxyl group of SKI Thr20, which forms a hydrogen bond with the Gln455 at the end of helix 5 of SMAD2, and is nearly completely buried in the interface (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). The two leucine residues (Leu21 and Leu32) that are mutated in SGS are both buried in the structure (<xref ref-type="fig" rid="fig5">Figure 5E,F</xref>). The structure we obtained is consistent with a SKI–SMAD2 MH2 domain structure that was published by others, while this work was in progress (<xref ref-type="bibr" rid="bib51">Miyazono et al., 2018</xref>). In that case, a pseudo-phosphorylated SMAD2 MH2 domain produced in <italic>Escherichia coli</italic> was used, complexed with a SKI peptide containing a C-terminal acidic tag (Ser-Asp-Glu-Asp).</p><p>Since our structure was generated with phosphorylated SMAD2, we were able to explore why SKI only binds phosphorylated R-SMADs and not monomeric unphosphorylated R-SMADs. To do this we compared the structure of the unphosphorylated SMAD2 MH2 domain bound to a region of ZFYVE9 (formerly called SARA) (<xref ref-type="bibr" rid="bib86">Wu et al., 2000</xref>) with our current structure of phosphorylated SMAD2 MH2 domain complexed with SKI. It was clear that in the unphosphorylated SMAD2 structure, Tyr268 in the so-called β1’ strand (amino acids 261–274) is locked in a stable conformation in a hydrophobic pocket, and also forms a number of hydrogen bonds (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Crucially, this conformation forces Trp448 into flattened orientation, which is incompatible with SKI binding through the pi-stacking involving SKI Phe24, SMAD2 Trp448, and SKI Pro35 (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). MH2 domain trimerization generates a new binding site for the β1’ strand on the adjacent MH2 domain subunit (<xref ref-type="fig" rid="fig5">Figure 5H</xref>; <xref ref-type="video" rid="video1">Video 1</xref>). The central residue driving this is Tyr268. In the trimer, the hydroxy group of Tyr268 makes hydrogen bond contact with the carbonyl group of Asp450 and the main chain of Lys451 on the adjacent MH2 domain subunit. As a consequence, Trp448 moves into an upright position in the trimer, allowing engagement with SKI. Thus, SKI can only bind SMAD2 in its phosphorylated trimeric state.</p><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-63545-video1.mp4"><label>Video 1.</label><caption><title>Mechanism of SKI binding to phosphorylated SMAD2 MH2 domain.</title><p>Animation of SMAD2 MH2 domain monomer (orange) forming a complex with two other SMAD2 MH2 domain monomers (cyan and olive). Note the movement of Trp448 on helix five and Tyr268 on the β1’ strand in the orange monomer upon trimerization. The flipped Trp448 is then in the correct orientation for binding to the SKI peptide (magenta).</p></caption></media></sec><sec id="s2-4"><title>Knockin of an SGS mutation into HEK293T cells inhibits Activin-induced SKI degradation and attenuates PSMAD3–SMAD4-mediated transcriptional activity</title><p>We have shown that the presence of SGS mutations prevent the interaction of SKI/SKIL with phosphorylated R-SMADs and have demonstrated that SKI/SKIL degradation requires an activated R-SMAD–SMAD4 complex. We therefore went on to investigate the functional effect of the SGS mutations on SKI degradation and TGF-β/Activin-induced transcriptional responses. To do this, we chose to focus on Pro35 because of its crucial role in forming the stacking interaction with Trp448 in SMAD2. In SGS patients, Pro35 is mutated to Ser or Gln (<xref ref-type="bibr" rid="bib8">Carmignac et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Doyle et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Schepers et al., 2015</xref>), substitutions not tolerated in activated R-SMAD–SMAD4 binding (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p><p>We used CRISPR/Cas9 technology with a single-stranded template oligonucleotide to knock in the Pro35 → Ser (P35S) mutation into HEK293T cells, and we efficiently generated a number of homozygous clones (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). In three independent clonal cell lines carrying the P35S SKI mutation, the binding to endogenous phosphorylated SMAD2 was severely compromised, compared with WT SKI (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The binding to SMAD4, however, was unchanged in the mutant cell lines, as the SGS mutations do not affect the SKI SAND domain, which is responsible for SMAD4 binding (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). To assess the impact of the P35S SKI mutation on the SKI and SKIL degradation, cells were treated with Activin for 1 or 2 hr and SKI/SKIL levels determined by immunoblotting. At both time points, we clearly demonstrated that P35S SKI levels remained stable, whilst in the parental cell lines, SKI protein is almost entirely degraded after 1 hr of Activin treatment (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The presence of mutated SKI had no effect on the Activin-induced degradation of SKIL in these lines (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Thus, the P35S mutation renders SKI completely resistant to ligand-induced degradation.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Knockin of an SGS mutation into SKI in HEK293T cells inhibits SKI degradation and inhibits Activin-induced transcription.</title><p>(<bold>A</bold>) Parental HEK293T and three independent P35S SKI knockin clones were incubated overnight with 10 μM SB-431542, washed out, and treated for 3 hr with 25 μM MG-132 and then with either SB-431542 or 20 ng/ml Activin A for an additional 1 hr. Whole-cell lysates were immunoprecipitated (IP) with SKI antibody or beads alone (Be). The IPs were immunoblotted using the antibodies shown. Inputs are shown below. (<bold>B</bold>) Parental HEK293T and four independent P35S SKI knockin clones were incubated with 10 μM SB-431542 overnight, washed out, and incubated with either SB-431542 or 20 ng/ml Activin for the times indicated. Whole-cell lysates were immunoblotted using the antibodies indicated. (<bold>C</bold>) Cells were treated as in (<bold>B</bold>), and nuclear lysates were prepared and analyzed by DNA pulldown assay using the wild-type c-Jun SBE oligonucleotide or a version mutated at the SMAD3–SMAD4 binding sites (top panel). Inputs are shown in the bottom panel. HEK293T parental and two independent P35S SKI knockin clones were stably transfected with the CAGA<sub>12</sub>-Luciferase reporters (<bold>D</bold>) or the BRE-Luciferase reporter (<bold>E</bold>) with TK-Renilla as an internal control. Cells were serum starved with media containing 0.5% fetal bovine serum and 10 μM SB-431542 overnight. Subsequently, cells were washed and treated with Activin A (<bold>D</bold>) or BMP4 (<bold>E</bold>) at the concentrations indicated for 8 hr. Cell lysates were prepared and assayed for Luciferase and Renilla activity. Plotted are the means and SEM of seven (<bold>D</bold>) or four (<bold>E</bold>) independent experiments, with the ratio of Luciferase:Renilla shown. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. The p-values are from two-way ANOVA with Tukey’s post hoc test. A, Activin; SB, SB-431542; Par, parental.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Luciferase assays for Activin A-induced HEK293T P35S SKI clones, as presented in <xref ref-type="fig" rid="fig6">Figure 6D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig6-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Luciferase assays for BMP4-induced HEK293T P35S SKI clones, as presented in <xref ref-type="fig" rid="fig6">Figure 6E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig6-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Mutation of the R-SMAD binding domain or SAND domain in SKI/SKIL prevents ligand-induced SKI/SKIL degradation.</title><p>(<bold>A</bold>) Characterization of P35S SKI mutation in HEK293T cells compared to parental cells by PCR followed by Sanger sequencing analysis. The black box indicates the change in nucleotides that give rise to the desired mutation. The details of the knocked in changes are given below. (<bold>B</bold>) HEK293T parental and SMAD4 knockout (S4 KO) cells were transiently transfected with FLAG-SKIL WT or FLAG-SKIL G103V (ΔS2/3) or FLAG-SKIL R314A, T315A, H317A, and W318E (ΔS4) as indicated, or left untransfected (U). Cells were incubated overnight with 10 μM SB-431542, then washed out, and pre-treated with 25 μM MG-132 for 3 hr, followed by incubation with SB-431542 or with 20 ng/ml Activin A for 1 hr. Whole cell extracts were immunoprecipitated (IP) with FLAG beads. The IPs were immunoblotted using the antibodies shown. Inputs are shown below. (<bold>C</bold>) HEK293T cells were untransfected (U) or transfected with the plasmids indicated as in (<bold>B</bold>). Cells were incubated overnight with 10 μM SB-431542, then washed out, and subsequently treated with SB-431542 or with 20 ng/ml Activin A for the times shown. Whole-cell extracts were immunoblotted using the antibodies shown. SB, SB-431542; A, Activin A.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig6-figsupp1-v2.tif"/></fig></fig-group><p>To determine whether SGS mutations had the same effect in SKIL, we introduced a G103V mutation into SKIL, corresponding to the SGS mutation G34V in SKI (referred to as SKIL ΔS2/3). Transfection of G103V SKIL in HEK293T cells led to reduction of SMAD2 binding in parental cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). The residual binding was mediated via SMAD2’s interaction with SMAD4, as it was lost in the SMAD4 knockout cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Binding of SMAD4 in the absence or presence of signal was unaffected by the mutation. As observed above for SKI, the SGS mutation in SKIL led to resistance to Activin-induced degradation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>), indicating that the R-SMAD interaction was essential. In addition, we made a version of SKIL with mutations in the SAND domain (R314A, T315A, H317A, and W318E) that rendered it unable to interact with SMAD4 (referred to as SKIL ΔS4). This mutant was also not degraded upon Activin stimulation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>), demonstrating an essential requirement for SMAD4 binding.</p><p>SKI and SKIL bind DNA in conjunction with SMAD4 at SBEs of TGF-β/Activin target genes in the absence of ligand stimulation. The ligand-induced degradation of SKI and SKIL then allows the activated R-SMAD–SMAD4 complexes access to the SBEs to activate transcription of target genes (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>; <xref ref-type="bibr" rid="bib73">Stroschein et al., 1999</xref>). We hypothesized that if the SGS mutations render SKI resistant to ligand-induced degradation, then mutant SKI and SMAD4 would remain bound to the DNA. To test this, we used a DNA pulldown assay with an oligonucleotide corresponding to SBEs from the <italic>JUN</italic> promoter (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>). Consistent with our prediction, both WT and P35S SKI bound the SBEs with SMAD4 in the absence of signal, but after Activin stimulation, the binding of WT SKI is lost, whilst the binding of P35S SKI is retained (<xref ref-type="fig" rid="fig6">Figure 6C</xref>).</p><p>The SKI–SMAD4 complex bound to SBEs in the absence of signal are transcriptionally repressive (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>; <xref ref-type="bibr" rid="bib73">Stroschein et al., 1999</xref>). Since P35S SKI remains bound with SMAD4 in Activin-stimulated cells, we reasoned that this would inhibit Activin-induced gene expression. To address this, we stably expressed luciferase reporters (CAGA<sub>12-</sub>Luciferase and BRE-Luciferase), together with TK-Renilla as an internal control (<xref ref-type="bibr" rid="bib15">Dennler et al., 1998</xref>; <xref ref-type="bibr" rid="bib34">Korchynskyi and ten Dijke, 2002</xref>), in parental HEK293T cells and in two independent clones of the knockin P35S SKI cells. The CAGA<sub>12</sub>-Luciferase reporter responds to TGF-β and Activin, is induced by PSMAD3–SMAD4 complexes, and is sensitive to SKI and SKIL levels, whilst the BRE-Luciferase reporter is induced by SMAD1/5–SMAD4 complexes in response to BMPs and is not affected by SKI and SKIL (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>). Strikingly, we found a significant reduction in Activin-induced CAGA<sub>12-</sub>Luciferase activity in the P35S SKI cells compared to the parental cell line (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), while BMP4-induced BRE-Luciferase activity was similar in all cell lines (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). The results indicate that SGS mutations in SKI lead to inhibition of TGF-β/Activin-induced transcription mediated by PSMAD3–SMAD4 complexes.</p></sec><sec id="s2-5"><title>Dermal fibroblasts from SGS patients exhibit an attenuated transcriptional TGF-β response</title><p>To gain further insights into the functional consequences of the SGS mutations, we obtained dermal fibroblasts from two SGS patients: a female carrying the heterozygous point mutation L32V and a male carrying a heterozygous deletion of 12 base pairs corresponding to codons 94–97 (ΔS94-97) (<xref ref-type="bibr" rid="bib8">Carmignac et al., 2012</xref>). Both patients present the classical features of SGS such as marfanoid habitus and intellectual disability, whilst the patient-carrying L32V mutation also manifests craniosynostosis. In addition, we obtained dermal fibroblast from a healthy male subject as a control.</p><p>We investigated whether the SGS mutations rendered SKI resistant to TGF-β-induced degradation in the dermal fibroblasts, as demonstrated in the knockin HEK293T cells. Indeed, in control fibroblasts, SKI expression is abrogated upon TGF-β stimulation after 1 hr, while in the SGS-derived fibroblasts, SKI protein remains relatively stable (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Note that these cells are heterozygous for the mutation, while the HEK293T P35S SKI knockins used above were homozygous, thus accounting for the incomplete SKI stabilization exhibited by the SGS fibroblasts, compared with the knockin cells.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>SGS mutations in SKI inhibit TGF-β-induced transcriptional responses in fibroblasts derived from SGS patients.</title><p>(<bold>A</bold>) Fibroblasts derived from a healthy subject carrying WT SKI and from two SGS patients carrying the L32V or the ΔS94-97 heterozygous mutations in SKI were incubated overnight with 10 μM SB-431542, washed out, and either re-incubated with SB-431542 or 2 ng/ml TGF-β for the times indicated. Whole-cell lysates were immunoblotted using the antibodies indicated. (<bold>B</bold>) Hierarchically clustered heatmaps of log<sub>2</sub>FC values (relative to the SB-431542-treated samples) showing the expression of TGF-β-responsive genes in the healthy fibroblasts and the L32V SKI fibroblasts after 1 hr and 8 hr of TGF-β treatment, analyzed by RNA-seq. Four biological replicates per condition were analyzed. The genes shown are those for which the TGF-β inductions were statistically significant in the healthy fibroblasts, but non-significant in the L32V fibroblasts. (<bold>C</bold>) The same data as in (<bold>B</bold>) are presented as box plots. (<bold>D</bold>) Model for the mechanism of action of WT SKI and mutated SKI. The left panel shows the unstimulated condition. In the nuclei, SKI (blue) is complexed with RNF111 (pink) and is also bound to DNA at SBEs with SMAD4 (green) forming a transcriptionally repressive complex with other transcriptional repressors (maroon). In the middle panel, TGF-β/Activin stimulation induces the formation of phosphorylated R-SMAD–SMAD4 complexes (yellow and green), which induce WT SKI degradation by RNF111. This allows an active PSMAD3–SMAD4 complex to bind SBEs and activate transcription. In the right panel, SGS-mutated SKI (light blue) is not degraded upon TGF-β/Activin stimulation, due to its inability to interact with PSMAD2 or PSMAD3. It therefore remains bound to SMAD4 on DNA, leading to attenuated transcriptional responses.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>RNA-seq raw data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Dermal fibroblasts from SGS patients exhibit an attenuated TGF-β transcriptional response.</title><p>(<bold>A</bold>) Principal component analysis (PCA) plot is shown for RNA-seq on normal fibroblasts containing WT SKI, and fibroblasts from SGS patients containing either the L32V SKI mutation or the ΔS94-97 SKI mutation, treated as indicated. PCA measures sample to sample variation using rlog transformed read count of all genes expressed above one read in at least one sample. Four replicates are shown for each condition. (<bold>B</bold>) Enriched Reactome pathways common between the pairwise comparisons of time points (SB-431542-treated versus 1 hr TGF-β or 8 hr TGF-β) of fibroblasts derived from a healthy subject containing WT SKI. (<bold>C</bold>) Hierarchically clustered heatmaps of log2FC values (relative to SB-431542 condition) showing the expression of TGF-β-responsive genes in the healthy (WT SKI) and the ΔS94-97 SKI-containing fibroblasts after 1 hr and 8 hr treatment with TGF-β, analyzed by RNA-seq. Four biological replicates per condition were analyzed. The genes shown are those for which the TGF-β inductions were statistically significant in the healthy fibroblasts, but non-significant in the ΔS94-97 fibroblasts. (<bold>D</bold>) The same data as in (<bold>C</bold>) are presented as box plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Validation of RNA-seq data by qPCR.</title><p>(<bold>A–L</bold>) Healthy dermal fibroblasts (WT SKI) and dermal fibroblasts from SGS patients containing either the L32V SKI mutation or the ΔS94-97 SKI mutation were treated overnight with 10 µM SB-431542, washed out, and incubated with either SB-431542 or 2 ng/ml TGF-β for 1 hr and 8 hr. Total RNA was extracted, and either RNA-seq or qPCR analysis was performed. Transcript levels for a subset of target genes are displayed as plots of the mean transcripts per million (TPM) from the RNA-seq data (<bold>A, C, E, G, I, K</bold>) or were measured by qPCR and plotted normalized to SB-431542-treated healthy fibroblasts (<bold>B, D, F, H, J, L</bold>). Plotted are the means and SEM of at least of four independent experiments. The p-values are from two-way ANOVA with Tukey’s post hoc test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>qPCR validations of RNA-seq data for SGS and control dermal fibroblasts.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63545-fig7-figsupp2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63545-fig7-figsupp2-v2.tif"/></fig></fig-group><p>To determine the effect of SKI stabilization on global TGF-β-induced transcription we performed genome-wide RNA-sequencing (RNA-seq) in three different conditions: SB-431542-treated cells (non-signaling condition), 1 hr TGF-β-treated and 8 hr TGF-β-treated, and compared the L32V and ΔS94-97 SKI fibroblasts to control fibroblasts. The samples separated in a principal component analysis according to the cell line used and the treatment performed (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>), and we confirmed that the differentially enriched genes after TGF-β treatment in the control fibroblasts were characteristic of pathways related to TGF-β signaling (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). We then performed a pairwise comparison between the TGF-β-treated and SB-431542-treated samples for each of the cell lines individually. We found that of the 339 genes that were differentially expressed in normal fibroblasts after 1 hr of TGF-β treatment, 60% (202 genes) were induced or repressed less efficiently in the L32V mutant fibroblasts, and of these, 97 genes were not significantly differentially expressed in the mutant cells at all (<xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>, <xref ref-type="fig" rid="fig7">Figure 7B,C</xref>). After an 8 hr TGF-β induction, we found that 4769 genes were differentially expressed in the normal fibroblasts, and of these 75% (3556 genes) were induced or repressed less efficiently in the L32V mutant cells, and 880 genes were not significantly differentially expressed in the mutant cells at all (<xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>, <xref ref-type="fig" rid="fig7">Figure 7B,C</xref>). We observed similar results when comparing the TGF-β responses in the normal fibroblasts versus ΔS94-97 SKI fibroblasts, although the effects were less dramatic (<xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C,D</xref>). To illustrate the magnitude of these effects we validated six gene expression profiles (<italic>ISLR2, CALB2, SOX11, ITGB6, HEY1, COL7A1</italic>) in the normal versus mutant fibroblasts by qPCR (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>).</p><p>Thus, we conclude that the presence of SGS point mutations in SKI that render it resistant to ligand-induced degradation, result in attenuated TGF-β responses for a substantial subset of target genes.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>SGS mutations in SKI lead to stabilization of SKI and attenuated TGF-β/Activin transcriptional responses</title><p>In this study, we have resolved the mechanism of action of SKI and the related protein SKIL, which has allowed us to elucidate the molecular consequences of SKI mutations in SGS. Our proposed mechanism of how SKI acts as a transcriptional repressor of TGF-β/Activin signaling in health and disease is illustrated in <xref ref-type="fig" rid="fig7">Figure 7D</xref>, and our results suggest that the mechanism of action of SKIL is equivalent. In the absence of ligand stimulation, in both healthy and diseased cells, SKI and SKIL bind in conjunction with SMAD4 at SBEs of TGF-β/Activin target genes. Here, they repress transcription by recruiting corepressors such as NCOR1 or SIN3A (<xref ref-type="bibr" rid="bib75">Tokitou et al., 1999</xref>; <xref ref-type="bibr" rid="bib56">Nomura et al., 1999</xref>; <xref ref-type="bibr" rid="bib73">Stroschein et al., 1999</xref>; <xref ref-type="bibr" rid="bib14">Deheuninck and Luo, 2009</xref>). We and others have also shown that in unstimulated cells, SKI and SKIL interact with the E3 ubiquitin ligase, RNF111, although this binding per se does not lead to SKI/SKIL degradation (<xref ref-type="bibr" rid="bib35">Le Scolan et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>; <xref ref-type="bibr" rid="bib53">Nagano et al., 2007</xref>). In healthy cells, upon TGF-β/Activin stimulation, SKI/SKIL form a complex with a canonical PSMAD2/PSMAD3–SMAD4 trimer, which induces rapid degradation of SKI/SKIL via RNF111 (<xref ref-type="bibr" rid="bib35">Le Scolan et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>; <xref ref-type="bibr" rid="bib53">Nagano et al., 2007</xref>). A possible mechanism explaining this would be that the binding of the PSMAD2/PSMAD3–SMAD4 complex induces an activating conformational change in RNF111, although this has not yet been demonstrated. Degradation of SKI and SKIL removes the repressors from the SBEs, allowing access of activated PSMAD3–SMAD4 complexes to the SBEs to regulate transcription of target genes. In SGS cells, mutated SKI can no longer interact with PSMAD2/PSMAD3, and it is therefore not degraded upon TGF-β/Activin signaling. It thus remains bound with SMAD4 to SBEs, resulting in an attenuation of TGF-β/Activin transcriptional responses. To demonstrate the functional consequences of the SGS mutations, we used genome-wide RNA-seq analysis of fibroblasts derived from SGS patients and have shown that SGS mutations indeed lead to a reduction in the magnitude of TGF-β transcriptional responses.</p></sec><sec id="s3-2"><title>The mechanism underlying SKI and SKIL function</title><p>Since the discovery that SKI and SKIL interact with SMAD2 and SMAD3, and act as negative regulators of TGF-β/Activin pathways (<xref ref-type="bibr" rid="bib42">Luo et al., 1999</xref>; <xref ref-type="bibr" rid="bib73">Stroschein et al., 1999</xref>; <xref ref-type="bibr" rid="bib74">Sun et al., 1999</xref>), two different mechanisms of action have been proposed. One mechanism is as described in the paragraph above – an initial version of which was first proposed in 1999 (<xref ref-type="bibr" rid="bib73">Stroschein et al., 1999</xref>). The second mechanism was based on the crystal structure of the SKI SAND domain with the MH2 domain of SMAD4 (<xref ref-type="bibr" rid="bib88">Wu et al., 2002</xref>). In this crystal structure, the binding of SKI with SMAD4, which is mediated via the I-loop of the SKI SAND domain with the L3 loop of SMAD4, was mutually exclusive with the binding of SMAD4 to activated R-SMADs, which also requires the L3 loop of SMAD4. Thus, the authors concluded that the mechanism whereby SKI (and by analogy, SKIL) inhibited TGF-β/Activin signaling was by binding to the activated R-SMADs and SMAD4 in such a way as to disrupt the phosphorylated R-SMAD–SMAD4 complexes required for transcriptional activation (<xref ref-type="bibr" rid="bib88">Wu et al., 2002</xref>). This mechanism has been supported by the observation that overexpression of SKI and SKIL inhibits TGF-β-induced functional responses (<xref ref-type="bibr" rid="bib43">Luo, 2004</xref>). The two mechanisms are fundamentally different. In the first, SKI and SKIL are constitutive repressors that need to be degraded to allow pathway activation. In the second, SKI and SKIL act as inducible repressors, as they repress only upon ligand induction, by virtue of their ability to disrupt activated SMAD complexes.</p><p>Our biochemical analysis of the role of SMAD4 in SKI/SKIL function now resolves the controversy between the two models. First, the efficient SKIL and SKI degradation that we and others have observed upon ligand stimulation in effect rules out the second model, at least in the first hours after ligand induction, as there would be little or no nuclear SKI or SKIL to disrupt activated SMAD complexes. Second, we clearly demonstrate for the first time that an intact functional phosphorylated R-SMAD–SMAD4 trimer is required to bind to SKIL to induce its ligand-dependent degradation. The key piece of evidence for this comes from our analysis of the inability of SMAD4 point mutants to restore ligand-induced SKIL degradation in SMAD4-null HaCaTs. Critically, we show that SMAD4 mutants that cannot form a canonical activated R-SMAD–SMAD4 trimer cannot rescue ligand-induced SKIL degradation, neither can SMAD4 mutants that do not interact with the SAND domain of SKIL. Thus, we conclude that TGF-β/Activin-induced SKIL degradation occurs only when SKIL interacts simultaneously with phosphorylated R-SMADs and with SMAD4, which in turn must interact with each other in a transcriptionally active trimer. This strongly indicates that SKIL binding to the R-SMAD–SMAD4 complex does not disrupt it.</p><p>This conclusion is supported by a recent crystal structure of the SAND domain of SKIL with the SMAD4 MH2 domain (<xref ref-type="bibr" rid="bib79">Walldén et al., 2017</xref>). This structure revealed that SKIL interacts with SMAD4 in two states: an ‘open’ and a ‘closed’ conformation. In the open conformation, the authors showed that SKIL can bind the R-SMAD–SMAD4 complex without intermolecular clashes or further structural readjustment, whereas in the closed state, structural reorganization within the SMAD heterotrimer is required to allow binding of SKIL, as has been observed in the previous structure of SKI with SMAD4 (<xref ref-type="bibr" rid="bib88">Wu et al., 2002</xref>). Molecular modelling has subsequently confirmed that SKIL in the open conformation forms a stable ternary SKIL–SMAD3–SMAD4 complex (<xref ref-type="bibr" rid="bib31">Ji et al., 2019</xref>). Furthermore, surface plasmon resonance indicated only one dominant binding mode for SKIL and SMAD4, leading to the conclusion that the open conformation is the biologically and functionally relevant mode and that the closed conformation may be the result of crystal packing forces (<xref ref-type="bibr" rid="bib79">Walldén et al., 2017</xref>). Note that the residues that allow the binding in the open conformation are highly conserved between SKI and SKIL, suggesting that both repressors bind to an intact activated R-SMAD–SMAD4 complex, which is required for their degradation. This would exclude the disruption model and thus favors the degradation model. It will now be important to solve the structure of an activated R-SMAD–SMAD4 trimer with the N-terminal half of SKI or SKIL that contains the R-SMAD binding motif, the DHD domain and the SAND domain that contacts the SMAD4 moiety. The role of the DHD domain is particularly intriguing as SGS mutations also occur in this domain (<xref ref-type="bibr" rid="bib8">Carmignac et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Doyle et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Schepers et al., 2015</xref>) and appear from our patient sample analysis to have a similar effect on inhibiting ligand-induced SKI degradation.</p><p>Our structural data also elegantly explain why SKI and SKIL only bind to phosphorylated SMAD2 and SMAD3 in the context of an activated SMAD trimer, and not to monomeric SMAD2 or SMAD3. The key residue for this discrimination is Trp448 in SMAD2, the equivalent of which would be Trp406 in SMAD3. In the trimer, this residue is in a conformation compatible with stacking between Phe24 and Pro35 of SKI. In the monomer, however, it is rotated approximately 90°, prohibiting SKI binding. The binding mode of SKI to SMAD2 is distinct from that of other SMAD2-binding partners, for example, the transcription factor FOXH1, which contains two binding motifs (<xref ref-type="bibr" rid="bib51">Miyazono et al., 2018</xref>). One of which, the so-called SIM, binds SMAD2 in both monomeric and trimeric forms, whilst the so-called FM only binds phosphorylated trimeric SMAD2 because it recognizes the interface of the SMAD trimer (<xref ref-type="bibr" rid="bib51">Miyazono et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Randall et al., 2002</xref>; <xref ref-type="bibr" rid="bib64">Randall et al., 2004</xref>). It will be interesting in the future to discover whether any other SMAD2/3-binding partner uses the same mode of interaction as SKI and SKIL.</p></sec><sec id="s3-3"><title>The molecular mechanism of SGS</title><p>As discussed in Introduction, SGS is a Marfan-related syndrome, with patients exhibiting many of the same features characteristic of MFS and LDS. These syndromes have been considered as TGF-β signalopathies, as the causal mutations are either direct components of the TGF-β signaling pathway or, as in the case of MFS, a component of the microfibrils in the ECM, FBN1, that is known to bind latent TGF-β in complex with latent TGF-β binding proteins (LTBPs) (<xref ref-type="bibr" rid="bib6">Cannaerts et al., 2015</xref>; <xref ref-type="bibr" rid="bib61">Ramirez et al., 2004</xref>; <xref ref-type="bibr" rid="bib66">Robertson et al., 2015</xref>). There has been controversy over whether the manifestations of these syndromes result from too little TGF-β signaling, or too much. This is obviously a crucial issue to resolve, as it is influencing the types of treatments being developed for patients with these syndromes.</p><p>The first suggestion that MFS resulted from excessive TGF-β came from mouse models, where key phenotypes could be rescued by a TGF-β neutralizing antibody (<xref ref-type="bibr" rid="bib27">Habashi et al., 2006</xref>; <xref ref-type="bibr" rid="bib54">Neptune et al., 2003</xref>). However, later studies using a potent murine anti-TGF-β antibody, or genetic methods for reducing TGF-β signaling have not corroborated these findings, and have worsened, rather than improved disease in MFS mouse models (<xref ref-type="bibr" rid="bib11">Cook et al., 2015b</xref>; <xref ref-type="bibr" rid="bib28">Holm et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Lindsay et al., 2012</xref>; <xref ref-type="bibr" rid="bib80">Wei et al., 2017</xref>). Furthermore, administration of small-molecule inhibitors of the TGF-β type I receptor, or a pan-TGF-β neutralizing antibody, has been associated with serious adverse cardiovascular toxicities, such as valve defects, similar to those found in MFS (<xref ref-type="bibr" rid="bib2">Anderton et al., 2011</xref>; <xref ref-type="bibr" rid="bib72">Stauber et al., 2014</xref>; <xref ref-type="bibr" rid="bib50">Mitra et al., 2020</xref>). The finding that mutations in FBN1 that prevent binding of LTBPs might result in lower levels of TGF-β signaling, rather than excessive signaling, is not so surprising given the more recent understanding of how TGF-β is activated. In order for mature TGF-β ligands to be released from the latent complex, either force has to be applied via integrins, to partially unfold the cleaved TGF-β pro-domain allowing release of the mature domain, or the pro-domain must be degraded by proteases (<xref ref-type="bibr" rid="bib18">Dong et al., 2017</xref>; <xref ref-type="bibr" rid="bib65">Rifkin et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Robertson and Rifkin, 2016</xref>). For the traction mechanism to occur, the integrin must be anchored to the actin cytoskeleton, and the LTBP must be tethered to ECM, via FBN1 and fibronectin. Thus, release of latent TGF-β alone is not therefore sufficient to produce active TGF-β ligands.</p><p>Consistent with the view that lower levels of TGF-β signaling might be responsible for MFS, the mutations that give rise to LDS are all loss-of-function mutations in TGF-β pathway components (<xref ref-type="bibr" rid="bib69">Schepers et al., 2018</xref>). Paradoxically though, signatures of higher TGF-β signaling were observed over time in mouse models of LDS (<xref ref-type="bibr" rid="bib22">Gallo et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">MacFarlane et al., 2019</xref>). However, in this case, the pathology could not be rescued by neutralizing TGF-β activity. One possibility with both the mouse models of MFS and LDS is that the mutations do initially lead to lowered TGF-β signaling, but over time cells compensate by up-regulating either TGF-β ligands themselves or other TGF-β family ligands that signal through PSMAD2/PSMAD3, ultimately leading to the enhanced signaling signatures observed.</p><p>With respect to SGS, there has been much less research into the consequences of the SGS mutations on TGF-β signaling responses. Based on the SMAD complex disruption model of SKI/SKIL action, it has been assumed that loss-of-function mutations in a negative regulator would lead to an increase in TGF-β signaling, and in fact, this has been used to support the idea that the Marfan-related syndromes are caused by excessive TGF-β signaling (<xref ref-type="bibr" rid="bib19">Doyle et al., 2012</xref>; <xref ref-type="bibr" rid="bib22">Gallo et al., 2014</xref>). Here we unequivocally show that the opposite is true. We demonstrate that these mutations lead to loss of ligand-induced SKI degradation. As a result, the stabilized SKI remains bound to SBEs with SMAD4 as a repressive complex, and hence, a subset of TGF-β/Activin transcriptional responses are attenuated. We have proven this in both HEK293T knockin cells and patient-derived fibroblasts. Moreover, we also find no evidence for increased PSMAD2 or PSMAD3 signaling. Indeed, neither model of SKI function would actually predict that the SKI mutations would affect levels of phosphorylated R-SMADs, since SKI acts downstream of R-SMAD phosphorylation. Finally, our finding that SGS mutations in SKI lead to its stabilization and are not equivalent to loss of SKI function also explains why patients with 1p36 deletion syndrome, who are haploinsufficient for SKI, do not have SGS. However, unsurprisingly, many of the same organs are affected in both syndromes (<xref ref-type="bibr" rid="bib9">Colmenares et al., 2002</xref>; <xref ref-type="bibr" rid="bib89">Zhu et al., 2013</xref>).</p><p>It will now be important to use animal models to explore how attenuation of transcription of specific TGF-β/Activin target genes leads to the manifestations of SGS, and to understand why SGS patients exhibit additional defects compared with LDS and MFS patients. We anticipate that our new understanding that the SKI mutations lead to attenuation of TGF-β responses will resolve the paradoxes surrounding the role of aberrant TGF-β signaling in the other Marfan-related disorders and will help inform the development of new therapeutic approaches.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell lines</title><p>HEK293T and HaCaT cells were obtained from the Francis Crick Institute Cell Services and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin (Pen/Strep). All CRISPR-Cas9 edited cell lines were cultured in the same media. Dermal fibroblasts from healthy subjects were kindly provided by David Abraham (UCL-Medical School Royal Free Campus) under the ethics of the Health Research Authority, NRES Committee London – Hampstead, Research Ethics Committee (REC) reference, 6398. L32V and ΔS94-97 SKI dermal fibroblasts were obtained from Laurence Faivre and Virginie Carmignac (Université de Bourgogne UMR1231 GAD, Dijon, France) under the ethics of the GAD collection, number DC2011-1332 (<xref ref-type="bibr" rid="bib8">Carmignac et al., 2012</xref>). The mutations were confirmed by Sanger sequencing and RNA sequencing. The fibroblasts were all cultured in DMEM supplemented with 10% FBS, 1% Pen/Strep, and 1% insulin–transferrin–selenium (Thermo Fisher). Mouse embryo-derived fibroblasts harboring the homozygous null allele <italic>Smad2<sup>ex2</sup></italic> (MEF SMAD2<sup>ex2</sup>) (<xref ref-type="bibr" rid="bib57">Piek et al., 2001</xref>) were maintained in DMEM supplemented with 10% FBS and 1% Pen/Strep. All cell lines have been banked by the Francis Crick Institute Cell Services and certified negative for mycoplasma. The identity of all cell lines was also authenticated by confirming that their responses to ligands and their phenotypes were consistent with published history. All the cell lines are listed in Key Resources Table.</p></sec><sec id="s4-2"><title>Ligands, chemicals, and cell treatments</title><p>Ligands and inhibitors were used at the following concentrations: TGF-β (PeproTech), 2 ng/ml; Activin A (PeproTech), 20 ng/ml; BMP4 (PeproTech), 20 ng/ml; SB-431542 (Tocris), 10 µM; MG-132 (Tocris), 25 µM. All treatments were performed in full serum or, where required, in serum-starved (0.5% FBS) DMEM. Unless otherwise stated, cells were incubated with 10 µM SB-431542 overnight to inhibit autocrine signalling, then were washed three times with warm media, and stimulated with either Activin A or TGF-β. For proteasome inhibition, cells were treated for 3 hr with 25 µM MG-132 prior stimulation with Activin A or TGF-β.</p></sec><sec id="s4-3"><title>Plasmids</title><p>Plasmids are listed in Key Resources Table. CAGA<sub>12</sub>-Luciferase, BRE-Luciferase, TK-Renilla, pEGFP-C1, and pEGFP-SMAD4 were as described previously (<xref ref-type="bibr" rid="bib15">Dennler et al., 1998</xref>; <xref ref-type="bibr" rid="bib34">Korchynskyi and ten Dijke, 2002</xref>; <xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>; <xref ref-type="bibr" rid="bib55">Nicolás et al., 2004</xref>). The pEGFP-SMAD4 mutants (D351H and D537Y) were generated by swapping the mutated SMAD4 coding region from the EF-HA vector into pEGFP-C1 (<xref ref-type="bibr" rid="bib13">De Bosscher et al., 2004</xref>). The pEGFP-SMAD4 SMAD4 mutants (A433E and I435Y) were generated by PCR using oligonucleotides listed in Key Resources Table. EF-Flag-SKIL G103V was generated from pEF-FLAG-SKIL by PCR using oligonucleotides listed in Key Resources Table, while the mutant containing the R314A, T315A, H317A, and W318E mutations was generated by synthesizing the SKIL region between BSTEII and AVRII sites containing the mutations and cloning that fragment into pEF-FLAG-SKIL. For plasmids used for generating recombinant proteins, see below.</p></sec><sec id="s4-4"><title>Transfections, generation of stable cell lines, and reporter assays</title><p>Cells were transfected with the appropriate plasmids using Fugene 6 (Roche) according to the manufacturer’s instructions. Luciferase reporter assays were performed as previously described, using the Dual-Glo assay system (Promega) following the manufacturer's instructions (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>).</p><p>HaCaT SMAD4 KO lines stably expressing either EGFP or EGFP-SMAD4 WT or mutants were generated by transfecting the cells with the appropriate plasmids. Transfected cells were selected with 500 µg/ml of G418 (Invitrogen), then FACS sorted for EGFP-positive cells, and expanded. EGFP expression was confirmed by microscopy. To generate stable HEK293T cell lines expressing either CAGA<sub>12</sub>-Luciferase or BRE-Luciferase together with TK-Renilla, cells were transfected with the appropriate plasmids together with a plasmid carrying the puromycin resistance gene (pSUPER-retro-puro; OligoEngine). Cells were then selected with 2 μg/ml puromycin (Sigma).</p></sec><sec id="s4-5"><title>CRISPR/Cas9-mediated knockout of SMADs in HEK293T and HaCaT cells</title><p>For the generation of knockin or knockout HEK293T cells, a parental clone was selected, which was a representative clone from the HEK293T pool that showed a robust Activin-induced SKI degradation and responded to TGF-β family ligands in the same way as the starting pool. For HaCaTs, a pool of cells was used as starting material for knockouts.</p><p>For SMAD2 and SMAD3 knockouts, a guide RNA in the MH2 domain of the protein was selected, whereas for SMAD4, two guide RNAs were picked, one targeting the MH1 domain and the other targeting at the end of the MH2 domain. The guide RNAs are shown in Key Resources Table. The guide RNAs were expressed from the plasmid pSpCas9(BB)−2A-GFP (pX458) (Addgene, #48138) (<xref ref-type="bibr" rid="bib62">Ran et al., 2013</xref>). HEK293T and HaCaT were transfected with the appropriate plasmid, and for the double knockout SMAD2 and SMAD3, the two plasmids were transfected simultaneously. Forty-eight hours after transfection, cells were sorted for EGFP expression, plated as single cells in 96-well plates, and screened by Western blot to assess the loss of the protein. For HEK293Ts, two knockout clones for SMAD2, SMAD3, SMAD2/SMAD3, and SMAD4 were used in these studies. For HaCaTs, four independent SMAD4 knockout clones were used. The sequences of the knockout alleles are shown in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p></sec><sec id="s4-6"><title>Knockin of P35S SKI at the endogenous locus</title><p>To introduce the P35S mutation into SKI, a gRNA was selected immediately downstream of codon 35. A 120 bp ssODN, where the codon CCG (P35) was mutated to TCC (S35) and codons 33 and 34 where silently mutated from GGC to GGA, was made and purified by Sigma (Key Resources Table). The ssODN contained phosphorothioate bonds between the first two and last two nucleotides at the 5′ and 3′ ends, respectively, to avoid ssODN degradation by endogenous nucleases. The silent mutations at codons 33 and 34 were introduced to increase the specificity of the downstream screening primer. The mutation at codon 35 also disrupts the PAM sequence.</p><p>Cells were cotransfected with the pX458 plasmid expressing the gRNA and 10 μM ssODN using Fugene 6. After 48 hr, cells were FACS sorted for GFP expression and plated as single cells in 96-well plates. Subsequently, clones were consolidated, and from replicate plates, genomic DNA was extracted using Quickextract DNA extraction solution (Lucigen) according to manufacturer’s instructions. PCR was performed using a universal reverse primer and two different forward primers: a primer which allows detection of WT SKI and one that detects the P35S SKI (Key Resources Table). Clones positive for P35S SKI knockin were selected, verified by Sanger Sequencing, and used for further analysis.</p></sec><sec id="s4-7"><title>Western blotting, immunoprecipitations, DNA pulldowns, and immunofluorescence</title><p>Whole-cell extracts were prepared as previously described (<xref ref-type="bibr" rid="bib30">Inman et al., 2002</xref>), while nuclear lysates were prepared according to <xref ref-type="bibr" rid="bib85">Wong et al., 1999</xref>. Western blots were carried out using standard methods. The list of the antibodies used is shown in Key Resources Table. Immunoprecipitations using GFP-Trap beads (Cromotek) were performed according to the manufacturer’s instructions. Immunoprecipitations using antibodies coupled to protein G-Sepharose beads (Sigma) were as described previously (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>).</p><p>DNA pulldown assays were performed as previously described with some modifications (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>). Nuclear lysates were extracted using buffer containing 360 mM NaCl, and the DNA pulldowns were performed in the presence of a 40 μg of non-biotinylated mutant oligonucleotide to reduce non-specific binding. The oligonucleotides corresponding to WT and mutated SBE of the <italic>JUN</italic> promoter are shown in Key Resources Table. Immunofluorescence was performed as previously described (<xref ref-type="bibr" rid="bib58">Pierreux et al., 2000</xref>), except that cells were washed and fixed for 5 min in methanol at −20 C (<xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref>). Nuclei were counter stained with DAPI (0.1 µ/ml). Imaging was performed on a Zeiss Upright 780 confocal microscope. Z-stacks were acquired for all channels, and maximum intensity projection images are shown.</p><p>For all of these techniques, a representative experiment of at least two biological repeats is shown.</p></sec><sec id="s4-8"><title>Flow cytometry</title><p>After 1 hr of TGF-β induction, HaCaT SMAD4 KO rescue cells, expressing either EGFP or EGFP-SMAD4 fusions, were washed, trypsinized, and pelleted. Cell pellets were fixed with methanol for 5 min at −20 C. Fixed cells were incubated with primary antibody against SKIL. Cells were then washed three times in phosphate-buffered saline (PBS) and incubated with secondary antibody conjugated with anti-rabbit Alexa 647. As a negative control, we used cells incubated with secondary antibody only. Antibodies used are listed in Key Resources Table. Subsequently, cells were washed three times with PBS, and pellets were resuspended with 500 µl of PBS and filtered to achieve a single-cell suspension. Cells were then analyzed for EGFP fluorescence on an LSRII flow cytometer (BD Biosciences), gated for viable, single cells. We then quantified the fluorescence emitted by Alexa 647 in cells expressing EGFP as a measure of SKIL protein. The FlowJo program was used to analyze the results.</p></sec><sec id="s4-9"><title>Peptide pulldown assays and peptide array</title><p>For peptide pulldowns, N-terminal biotinylated peptides were synthesized by the Peptide Chemistry Facility at the Francis Crick Institute using standard procedures. The peptide pulldown assays were performed as described previously (<xref ref-type="bibr" rid="bib63">Randall et al., 2002</xref>). Where recombinant protein was used, it was dissolved in buffer Y (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% [vol/vol] NP-40) and used at the concentrations given in the legend to <xref ref-type="fig" rid="fig4">Figure 4</xref>. Peptides sequences are given in Key Resources Table.</p><p>A peptide array was generated using peptides corresponding to SKI amino acids 11–45, of which the amino acids 19–35 were mutated one by one to every other amino acid. Arrays were synthesized on an Intavis ResPepSL Automated Peptide Synthesiser (Intavis Bioanalytical Instruments, Germany) on a cellulose membrane by cycles of N(a)-Fmoc amino acids coupling via activation of carboxylic acid groups with diisopropylcarbodiimide in the presence of hydroxybenzotriazole (HOBt), followed by removal of the temporary α-amino protecting group by piperidine treatment. Subsequent to chain assembly, side chain protection groups were removed by treatment of membranes with a deprotection cocktail (20 ml 95% trifluoroacetic acid, 3% triisopropylsilane, 2% water for 4 hr at room temperature) and then washed (4 x dichloromethane, 4 x ethanol, 2 x water, 1 x ethanol), prior to being air dried.</p><p>Peptide array membranes were blocked with 5% Milk in 0.01% Tween 20 in PBS and then incubated with purified PSMAD3–SMAD4 complex (see below) overnight. Subsequently, the membranes were washed and incubated with an antibody against SMAD2/3 (BD Biosciences) conjugated to Alexa 488 using a Zenon Mouse IgG Labeling Kit (Life Technology) according to the manufacturer’s instructions. Fluorescence was detected where binding occurred between SKI and PSMAD3–SMAD4 complex and measured with a Typhoon FLA 9500 biomolecular imager (GE Healthcare).</p><p>In all peptide experiments, a representative of at least two biological repeats is shown.</p></sec><sec id="s4-10"><title>Generation of phosphorylated SMAD2 MH2 domain in insect cells</title><p>The cDNA encoding a fusion protein consisting of GST followed by a 3C cleavage site and the human SMAD2 MH2 domain (residues 241–465) was inserted into the MCSI of the pFastBac Dual vector (Thermo Fisher Scientific) in the Sal1 and Spe1 restriction sites. The cDNA encoding a constitutively active version of the human TGFBR1 kinase domain (residues 175–503 with a T204D mutation) was cloned into the MCSII using the SmaI and SphI restriction sites. A high-titre baculovirus (&gt;10<sup>8</sup> pfu/ml) was generated using standard published protocols (<xref ref-type="bibr" rid="bib21">Fitzgerald et al., 2006</xref>). Expression of the trimeric phosphorylated SMAD2 MH2 domain was performed by infecting Sf21 cells at a density of 1.5 × 10<sup>6</sup> cells/ml at a MOI: 1 and incubating for 72 hr at 27°C with rotation at 110 r.p.m. Cells were harvested by centrifugation at 1000 × g for 10 min and stored at −80°C until required.</p></sec><sec id="s4-11"><title>Expression of the human phosphorylated SMAD3–SMAD4 complex</title><p>An expression construct was generated encoding GST-fused full-length human SMAD3 (with 3C protease site) and inserted into the MCSI of the pFastBac dual. As with the SMAD2 MH2 domain construct, the constitutively active human TGFBR1 kinase domain was cloned into MCSII. Another vector encoding full-length human SMAD4 alone was also constructed, where SMAD4 was inserted into the pBacPAK plasmid. The resulting vectors were used to generate high-titre virus (&gt;10<sup>8</sup> pfu/ml) using a standard published protocol. For expression of the phosphorylated SMAD3–SMAD4 complex both viruses were used to infect cultures of Sf21 insect cells at a density of 1.5 × 10<sup>6</sup> cells/ml at a MOI: 1. Infected cultures were allowed to grow for 72 hr at 27°C with rotation at 110 r.p.m. Cells were harvested by centrifugation at 1000 x g for 10 min and stored at −80°C until required.</p></sec><sec id="s4-12"><title>Purification of trimeric phosphorylated SMAD2 MH2 domain and phosphorylated SMAD3–SMAD4 complexes</title><p>The same procedure was used to purify both phosphorylated SMAD2 MH2 domain trimers and phosphorylated SMAD3–SMAD4 complexes. Typically, 500 ml of infected Sf21 cells were lysed in 30 ml of a lysis buffer consisting of 50 mM HEPES (pH 8.0), 250 mM NaCl, 10% (vol/vol) glycerol, 1% (vol/vol) Triton X-100, 10 mM β-glycerophosphate, 1 mM NaF, 10 mM benzamidine, and 1 mM dithiothreitol (DTT) supplemented with 5 µl BaseMuncher (2500 U/µl), 5 mM MgCl<sub>2</sub>, and phosphatase (phosphatase inhibitor cocktail 3, Sigma) and protease inhibitors (EDTA-free cOmplete protease inhibitors, Roche). After incubation for 20 min, the suspension was sonicated to ensure complete lysis. The insoluble fraction was pelleted by centrifugation (100,000 × g at 4°C for 30 min). The soluble fraction was incubated with 500 µl bed volume of Glutathione 4B Sepharose (Cytiva) for 2 hr at 4°C with gentle agitation. The resin was washed extensively with buffer containing 50 mM HEPES (pH 7.5), 200 mM NaCl, and 1 mM DTT. The phosphorylated SMAD2 MH2 domain or phosphorylated SMAD3–SMAD4 complexes were eluted from the GSH resin by cleavage with GST-3C protease (20 µg) in 5 ml wash buffer overnight at 4°C with gentle agitation. The proteins were concentrated to 0.5 ml and applied to a S200 10/300 Increase (Cytiva) size exclusion column equilibrated with 50 mM HEPES (pH 7.5), 200 mM NaCl, 5% (vol/vol) glycerol, and 1 mM DTT. Fractions were analyzed by SDS–PAGE and concentrated to 2 mg/ml and snap frozen as 50 µl aliquots and stored at −80°C until required. Purified phosphorylated SMAD2 MH2 domain was quantified using a molar extinction coefficient value of 39,420 M<sup>−1</sup>cm<sup>−1</sup>. The molar extinction coefficients used for SMAD3 and SMAD4 were 68,870 and 70,820 M<sup>−1</sup>cm<sup>−1</sup>, respectively.</p></sec><sec id="s4-13"><title>Size exclusion chromatography with multiangle laser light scattering</title><p>The trimeric arrangement of the phosphorylated SMAD2 MH2 domain was confirmed by SEC-MALLS. In brief, an S200 10/300 Increase column was attached to an AKTA Micro FPLC system (GE Healthcare), which was connected to a Heleos Dawn 8+ followed by an Optilab TRex (Wyatt). For data collection, 100 µl of a 2 mg/ml stock of phosphorylated SMAD2 MH2 domain was injected and data collected at 0.5 ml/min for 60 min. The data were analyzed by ASTRA6.1 software.</p></sec><sec id="s4-14"><title>Biolayer interferometry</title><p>Biolayer interferometry was carried out using an Octet RED96 instrument (ForteBio). Biotinylated N-SKI peptide (residues 11–45) was immobilized on streptavidin-coated biosensors (ForteBio) at a concentration of 1 μg/ml in buffer containing 50 mM HEPES pH 7.5, 200 mM NaCl, 1 mg/ml bovine serum albumin, and 0.1% Tween-20 for 100 s. The immobilization typically reached a response level of 2 nm. Association and dissociation curves were obtained through addition of a dilution series of trimeric phosphorylated SMAD2 MH2 domain complex (15.6–1.95 μM) for 100 s followed by dissociation in buffer for 350 s using the Octet acquisition software. The binding data were fitted using the Octet analysis software.</p></sec><sec id="s4-15"><title>Crystallization of the N-SKI–SMAD2 MH2 domain complex</title><p>The SKI peptide (amino acids 11–45) was synthesized by the Peptide Chemistry Group and added in a 2:1 ratio to the phosphorylated SMAD2 MH2 domain trimer. The complex was concentrated to 6 mg/ml and subject to crystallization trials. Initial screening gave rise to fine needles, in several conditions, and these were used as seedstock for rescreening. This gave rise to 25 µm crystals, with a cubic morphology, in the Crystal Screen Cryo screen (Hampton Research); the condition being 1.5 M ammonium sulphate, 0.15 M K Na tartrate, 0.08 M Na<sub>3</sub>citrate, and 25% (vol/vol) glycerol. The crystals were flash-frozen in liquid nitrogen, and data were collected on the I24 beamline at Diamond Light Source (DLS). Data was processed automatically using the DLS Xia2/XDS pipeline (<xref ref-type="bibr" rid="bib84">Winter, 2010</xref>; <xref ref-type="bibr" rid="bib33">Kabsch, 2010</xref>). The crystals belong to the I2<sub>1</sub>3 space group and diffracted to a resolution of 2.0 Å.</p></sec><sec id="s4-16"><title>Structure determination</title><p>Molecular replacement was undertaken with the CCP4 program Phaser (<xref ref-type="bibr" rid="bib47">McCoy et al., 2007</xref>), utilising pdbfile 1khx (with the C-terminal tail removed), as the search model (<xref ref-type="bibr" rid="bib83">Winn et al., 2011</xref>). Initial structure refinement was undertaken with Refmac (<xref ref-type="bibr" rid="bib52">Murshudov et al., 2011</xref>), with manual model building in Coot (<xref ref-type="bibr" rid="bib20">Emsley et al., 2010</xref>), before switching to Phenix.Refine to finalize the model (<xref ref-type="bibr" rid="bib38">Liebschner et al., 2019</xref>; <xref ref-type="bibr" rid="bib1">Afonine et al., 2012</xref>). Coordinates and data are available from the Protein Data Bank, with accession code: 6ZVQ.</p></sec><sec id="s4-17"><title>RNA extraction, qRT-PCR, and RNA-sequencing</title><p>Total RNA was extracted using Trizol (Thermo Fisher Scientific) according to the manufacturer’s instructions. cDNA synthesis and qPCRs were performed as described (<xref ref-type="bibr" rid="bib25">Grönroos et al., 2012</xref>). Primer sequences are listed in Key Resources Table. All qPCRs were performed with the PowerUp SYBR Green Master Mix (Thermo Fisher Scientific) with 300 nM of each primer and 2 µl of diluted cDNA. Fluorescence acquisition was performed on either a 7500 FAST machine or QuantStudio 12 Flex (Thermo Fisher Scientific). Calculations were performed using the ΔΔCt method, and levels of mRNA are expressed as fold change relative to untreated or SB-431542-treated control cells. Means ± SEM from at least three independent experiments are shown. Results were analyzed using GraphPad Prism 8 software and statistics were performed on these data using one-way or two-way analysis of variance (ANOVA) as stated in the figure legends.</p><p>For the RNA-sequencing experiment four biological replicates were used. Total RNA was extracted, and the quality of the RNA was assessed using a bioanalyzer (Agilent). Libraries were prepared using the KAPA mRNA HyperPrep kit (Roche), and single-end reads were generated using an Illumina HiSeq 4000.</p></sec><sec id="s4-18"><title>RNA sequencing analysis</title><p>Raw reads were quality and adapter trimmed using cutadapt-1.9.1 (<xref ref-type="bibr" rid="bib45">Martin, 2011</xref>) prior to alignment. Reads were then aligned and quantified using RSEM-1.3.0/STAR-2.5.2 (<xref ref-type="bibr" rid="bib17">Dobin et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Li and Dewey, 2011</xref>) against the human genome GRCh38 and annotation release 89, both from Ensembl. TPM (transcripts per kilobase million) values were also generated using RSEM/STAR. Differential gene expression analysis was performed in R-3.6.1 (<xref ref-type="bibr" rid="bib59">R Development Core Team, 2009</xref>) using the DESeq2 package (version 1.24.0) (<xref ref-type="bibr" rid="bib41">Love et al., 2014</xref>). Differential genes were selected using a 0.05 false discovery rate threshold using the pairwise comparisons between time points within each cell line individually. Normalization and variance-stabilizing transformation was applied on raw counts before performing principal component analysis and Euclidean distance-based clustering.</p><p>For the heatmaps, we selected those genes that were significantly differentially expressed in the control cell line with an absolute log2 (fold change) of at least 0.5, not significantly differentially expressed in the SKI-mutated cell lines, and detected with at least a TPM value of 2 in the control cell lines in any condition. We then visualized the log2 (fold change) for each time point against the control condition. Heatmaps were generated in R-3.6.1 using the ComplexHeatmap (<xref ref-type="bibr" rid="bib26">Gu et al., 2016</xref>) package (version 2.0.0). The raw data files have been uploaded to the European Genome-phenome Archive (EGA), accession number EGAS00001004908.</p></sec><sec id="s4-19"><title>Quantifications</title><p>Quantification of Western blots was performed by densitometry measurements of each lane using ImageJ software. The measurements were normalized to the loading control in the same blot. In each case, quantifications were normalized to the SB-431542-treated samples. Quantification for the flow cytometry was performed by measurement of the fluorescence emitted by Alexa 647 in EGFP-expressing single cells as a measure of SKIL protein, and levels were normalized to the SB-431542-treated sample in the SMAD4 knockout cells. The program FlowJo was used to analyze the results. For the peptide arrays, two independent experiments were quantified. The staining intensity of each array was quantified by systematically moving a circular selection (diameter 20 pixels) across the array and measuring the 8-bit greyscale intensity for each spot. Each intensity measure was normalized to the average intensity of 60 positive controls of the WT peptide after subtracting the background, measured from the average intensity of 60 negative controls (truncated SKI peptide C as indicated in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>).</p></sec><sec id="s4-20"><title>Statistical analysis</title><p>Statistical analysis was performed in Prism 8 (GraphPad). At least three independent experiments were performed for statistical analysis unless otherwise specified in the figure legends. Normalized values were log transformed for the statistical analysis. For comparison between more than two groups with one variable, one-way ANOVA was used followed by the Sidak’s correction test. For comparison between groups that have been split on two independent variables, two-way ANOVA was performed followed by Tukey’s multiple comparison tests.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We would like to thank David Abraham for the normal dermal fibroblasts. We are very grateful to the Francis Crick Institute Advanced Sequencing Facility, the Light Microscopy Facility, the Flow Cytometry Facility, Cell Services, the Genomics Equipment Park and to the Peptide Chemistry Facility. We thank Andrew Economou for quantification of the peptide arrays. We thank all the members of the Hill lab and Davide Coda, Daniel Miller, and Anassuya Ramachandran for helpful discussions and very useful comments on the manuscript. This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001095), the UK Medical Research Council (FC001095), and the Wellcome Trust (FC001095).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con10"><p>Supervision, Project administration</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: Dermal fibroblasts from healthy subjects were kindly provided by David Abraham (UCL-Medical School Royal Free Campus) under the ethics of the Health Research Authority, NRES Committee London - Hampstead, Research Ethics Committee (REC) reference, 6398. L32V and ΛS94-97 SKI dermal fibroblasts were obtained from Laurence Faivre and Virginie Carmignac (Université de Bourgogne UMR1231 GAD, Dijon, France) under the ethics of the GAD collection, number DC2011-1332 (Carmignac et al., 2012).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-63545-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data have been uploaded to the European Genome-phenome Archive (EGA), accession number EGAS00001004908. Diffraction data have been deposited in PDB under the accession code 6ZVQ. All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1, 2, 4, 5, 6, 7, Figure 1 Supplement 1, Figure 2 Supplement 1, Figure 7 Supplement 2.</p><p>The following datasets were generated:</p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Gori</surname><given-names>I</given-names></name><name><surname>George</surname><given-names>R</given-names></name><name><surname>Purkiss</surname><given-names>AG</given-names></name><name><surname>Strohbuecker</surname><given-names>S</given-names></name><name><surname>Randall</surname><given-names>RA</given-names></name><name><surname>Ogrodowicz</surname><given-names>R</given-names></name><name><surname>Carmignac</surname><given-names>V</given-names></name><name><surname>Faivre</surname><given-names>L</given-names></name><name><surname>Joshi</surname><given-names>D</given-names></name><name><surname>Kjær</surname><given-names>S</given-names></name><name><surname>Hill</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Mutations in SKI in Shprintzen-Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization</data-title><source>European Genome-Phenome Archive</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/ega/studies/EGAS00001004908">EGAS00001004908</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Purkiss</surname><given-names>AG</given-names></name><name><surname>Kjær</surname><given-names>S</given-names></name><name><surname>George</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Complex betweenSMAD2 MH2 domain and peptide from Ski corepressor</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/6ZVQ">6ZVQ</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonine</surname> <given-names>PV</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>Echols</surname> <given-names>N</given-names></name><name><surname>Headd</surname> <given-names>JJ</given-names></name><name><surname>Moriarty</surname> <given-names>NW</given-names></name><name><surname>Mustyakimov</surname> <given-names>M</given-names></name><name><surname>Terwilliger</surname> <given-names>TC</given-names></name><name><surname>Urzhumtsev</surname> <given-names>A</given-names></name><name><surname>Zwart</surname> <given-names>PH</given-names></name><name><surname>Adams</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Towards automated crystallographic structure refinement with <italic>phenix.refine</italic></article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>68</volume><fpage>352</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1107/S0907444912001308</pub-id><pub-id pub-id-type="pmid">22505256</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderton</surname> <given-names>MJ</given-names></name><name><surname>Mellor</surname> <given-names>HR</given-names></name><name><surname>Bell</surname> <given-names>A</given-names></name><name><surname>Sadler</surname> <given-names>C</given-names></name><name><surname>Pass</surname> <given-names>M</given-names></name><name><surname>Powell</surname> <given-names>S</given-names></name><name><surname>Steele</surname> <given-names>SJ</given-names></name><name><surname>Roberts</surname> <given-names>RR</given-names></name><name><surname>Heier</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Induction of heart valve lesions by small-molecule ALK5 inhibitors</article-title><source>Toxicologic Pathology</source><volume>39</volume><fpage>916</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1177/0192623311416259</pub-id><pub-id pub-id-type="pmid">21859884</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelov</surname> <given-names>SN</given-names></name><name><surname>Hu</surname> <given-names>JH</given-names></name><name><surname>Wei</surname> <given-names>H</given-names></name><name><surname>Airhart</surname> <given-names>N</given-names></name><name><surname>Shi</surname> <given-names>M</given-names></name><name><surname>Dichek</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TGF-β (Transforming growth Factor-β) Signaling protects the thoracic and abdominal aorta from angiotensin II-Induced pathology by distinct mechanisms</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>37</volume><fpage>2102</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309401</pub-id><pub-id pub-id-type="pmid">28729364</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnon</surname> <given-names>C</given-names></name><name><surname>Atanasoski</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>c-Ski in health and disease</article-title><source>Cell and Tissue Research</source><volume>347</volume><fpage>51</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1007/s00441-011-1180-z</pub-id><pub-id pub-id-type="pmid">21647564</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briones-Orta</surname> <given-names>MA</given-names></name><name><surname>Levy</surname> <given-names>L</given-names></name><name><surname>Madsen</surname> <given-names>CD</given-names></name><name><surname>Das</surname> <given-names>D</given-names></name><name><surname>Erker</surname> <given-names>Y</given-names></name><name><surname>Sahai</surname> <given-names>E</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Arkadia regulates tumor metastasis by modulation of the TGF-β pathway</article-title><source>Cancer Research</source><volume>73</volume><fpage>1800</fpage><lpage>1810</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-1916</pub-id><pub-id pub-id-type="pmid">23467611</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannaerts</surname> <given-names>E</given-names></name><name><surname>van de Beek</surname> <given-names>G</given-names></name><name><surname>Verstraeten</surname> <given-names>A</given-names></name><name><surname>Van Laer</surname> <given-names>L</given-names></name><name><surname>Loeys</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TGF-β signalopathies as a paradigm for translational medicine</article-title><source>European Journal of Medical Genetics</source><volume>58</volume><fpage>695</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2015.10.010</pub-id><pub-id pub-id-type="pmid">26598797</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname> <given-names>S</given-names></name><name><surname>Robertson</surname> <given-names>SP</given-names></name><name><surname>Daniel</surname> <given-names>PB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title><italic>TGFBR1</italic> mutations associated with Loeys-Dietz syndrome are inactivating</article-title><source>Journal of Receptors and Signal Transduction</source><volume>32</volume><fpage>150</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.3109/10799893.2012.664553</pub-id><pub-id pub-id-type="pmid">22414221</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmignac</surname> <given-names>V</given-names></name><name><surname>Thevenon</surname> <given-names>J</given-names></name><name><surname>Adès</surname> <given-names>L</given-names></name><name><surname>Callewaert</surname> <given-names>B</given-names></name><name><surname>Julia</surname> <given-names>S</given-names></name><name><surname>Thauvin-Robinet</surname> <given-names>C</given-names></name><name><surname>Gueneau</surname> <given-names>L</given-names></name><name><surname>Courcet</surname> <given-names>JB</given-names></name><name><surname>Lopez</surname> <given-names>E</given-names></name><name><surname>Holman</surname> <given-names>K</given-names></name><name><surname>Renard</surname> <given-names>M</given-names></name><name><surname>Plauchu</surname> <given-names>H</given-names></name><name><surname>Plessis</surname> <given-names>G</given-names></name><name><surname>De Backer</surname> <given-names>J</given-names></name><name><surname>Child</surname> <given-names>A</given-names></name><name><surname>Arno</surname> <given-names>G</given-names></name><name><surname>Duplomb</surname> <given-names>L</given-names></name><name><surname>Callier</surname> <given-names>P</given-names></name><name><surname>Aral</surname> <given-names>B</given-names></name><name><surname>Vabres</surname> <given-names>P</given-names></name><name><surname>Gigot</surname> <given-names>N</given-names></name><name><surname>Arbustini</surname> <given-names>E</given-names></name><name><surname>Grasso</surname> <given-names>M</given-names></name><name><surname>Robinson</surname> <given-names>PN</given-names></name><name><surname>Goizet</surname> <given-names>C</given-names></name><name><surname>Baumann</surname> <given-names>C</given-names></name><name><surname>Di Rocco</surname> <given-names>M</given-names></name><name><surname>Sanchez Del Pozo</surname> <given-names>J</given-names></name><name><surname>Huet</surname> <given-names>F</given-names></name><name><surname>Jondeau</surname> <given-names>G</given-names></name><name><surname>Collod-Beroud</surname> <given-names>G</given-names></name><name><surname>Beroud</surname> <given-names>C</given-names></name><name><surname>Amiel</surname> <given-names>J</given-names></name><name><surname>Cormier-Daire</surname> <given-names>V</given-names></name><name><surname>Rivière</surname> <given-names>JB</given-names></name><name><surname>Boileau</surname> <given-names>C</given-names></name><name><surname>De Paepe</surname> <given-names>A</given-names></name><name><surname>Faivre</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>In-frame mutations in exon 1 of SKI cause dominant Shprintzen-Goldberg syndrome</article-title><source>The American Journal of Human Genetics</source><volume>91</volume><fpage>950</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2012.10.002</pub-id><pub-id pub-id-type="pmid">23103230</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colmenares</surname> <given-names>C</given-names></name><name><surname>Heilstedt</surname> <given-names>HA</given-names></name><name><surname>Shaffer</surname> <given-names>LG</given-names></name><name><surname>Schwartz</surname> <given-names>S</given-names></name><name><surname>Berk</surname> <given-names>M</given-names></name><name><surname>Murray</surname> <given-names>JC</given-names></name><name><surname>Stavnezer</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Loss of the SKI proto-oncogene in individuals affected with 1p36 deletion syndrome is predicted by strain-dependent defects in ski-/- mice</article-title><source>Nature Genetics</source><volume>30</volume><fpage>106</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/ng770</pub-id><pub-id pub-id-type="pmid">11731796</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname> <given-names>JR</given-names></name><name><surname>Carta</surname> <given-names>L</given-names></name><name><surname>Galatioto</surname> <given-names>J</given-names></name><name><surname>Ramirez</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Cardiovascular manifestations in marfan syndrome and related diseases; multiple genes causing similar phenotypes</article-title><source>Clinical Genetics</source><volume>87</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/cge.12436</pub-id><pub-id pub-id-type="pmid">24867163</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname> <given-names>JR</given-names></name><name><surname>Clayton</surname> <given-names>NP</given-names></name><name><surname>Carta</surname> <given-names>L</given-names></name><name><surname>Galatioto</surname> <given-names>J</given-names></name><name><surname>Chiu</surname> <given-names>E</given-names></name><name><surname>Smaldone</surname> <given-names>S</given-names></name><name><surname>Nelson</surname> <given-names>CA</given-names></name><name><surname>Cheng</surname> <given-names>SH</given-names></name><name><surname>Wentworth</surname> <given-names>BM</given-names></name><name><surname>Ramirez</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for marfan syndrome</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>35</volume><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.305150</pub-id><pub-id pub-id-type="pmid">25614286</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname> <given-names>D</given-names></name><name><surname>Randall</surname> <given-names>RA</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>An N-terminally truncated Smad2 protein can partially compensate for loss of full-length Smad2</article-title><source>Biochemical Journal</source><volume>417</volume><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1042/BJ20080014</pub-id><pub-id pub-id-type="pmid">18764783</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bosscher</surname> <given-names>K</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name><name><surname>Nicolas</surname> <given-names>FJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells</article-title><source>Biochemical Journal</source><volume>379</volume><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1042/bj20031886</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deheuninck</surname> <given-names>J</given-names></name><name><surname>Luo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ski and SnoN, potent negative regulators of TGF-β signaling</article-title><source>Cell Research</source><volume>19</volume><fpage>47</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.324</pub-id><pub-id pub-id-type="pmid">19114989</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennler</surname> <given-names>S</given-names></name><name><surname>Itoh</surname> <given-names>S</given-names></name><name><surname>Vivien</surname> <given-names>D</given-names></name><name><surname>Ten Dijke</surname> <given-names>P</given-names></name><name><surname>Huet</surname> <given-names>S</given-names></name><name><surname>Gauthier</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene</article-title><source>The EMBO Journal</source><volume>17</volume><fpage>3091</fpage><lpage>3100</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.11.3091</pub-id><pub-id pub-id-type="pmid">9606191</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietz</surname> <given-names>HC</given-names></name><name><surname>Cutting</surname> <given-names>GR</given-names></name><name><surname>Pyeritz</surname> <given-names>RE</given-names></name><name><surname>Maslen</surname> <given-names>CL</given-names></name><name><surname>Sakai</surname> <given-names>LY</given-names></name><name><surname>Corson</surname> <given-names>GM</given-names></name><name><surname>Puffenberger</surname> <given-names>EG</given-names></name><name><surname>Hamosh</surname> <given-names>A</given-names></name><name><surname>Nanthakumar</surname> <given-names>EJ</given-names></name><name><surname>Curristin</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene</article-title><source>Nature</source><volume>352</volume><fpage>337</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/352337a0</pub-id><pub-id pub-id-type="pmid">1852208</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>X</given-names></name><name><surname>Zhao</surname> <given-names>B</given-names></name><name><surname>Iacob</surname> <given-names>RE</given-names></name><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Koksal</surname> <given-names>AC</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Engen</surname> <given-names>JR</given-names></name><name><surname>Springer</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Force interacts with macromolecular structure in activation of TGF-β</article-title><source>Nature</source><volume>542</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/nature21035</pub-id><pub-id pub-id-type="pmid">28117447</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname> <given-names>AJ</given-names></name><name><surname>Doyle</surname> <given-names>JJ</given-names></name><name><surname>Bessling</surname> <given-names>SL</given-names></name><name><surname>Maragh</surname> <given-names>S</given-names></name><name><surname>Lindsay</surname> <given-names>ME</given-names></name><name><surname>Schepers</surname> <given-names>D</given-names></name><name><surname>Gillis</surname> <given-names>E</given-names></name><name><surname>Mortier</surname> <given-names>G</given-names></name><name><surname>Homfray</surname> <given-names>T</given-names></name><name><surname>Sauls</surname> <given-names>K</given-names></name><name><surname>Norris</surname> <given-names>RA</given-names></name><name><surname>Huso</surname> <given-names>ND</given-names></name><name><surname>Leahy</surname> <given-names>D</given-names></name><name><surname>Mohr</surname> <given-names>DW</given-names></name><name><surname>Caulfield</surname> <given-names>MJ</given-names></name><name><surname>Scott</surname> <given-names>AF</given-names></name><name><surname>Destrée</surname> <given-names>A</given-names></name><name><surname>Hennekam</surname> <given-names>RC</given-names></name><name><surname>Arn</surname> <given-names>PH</given-names></name><name><surname>Curry</surname> <given-names>CJ</given-names></name><name><surname>Van Laer</surname> <given-names>L</given-names></name><name><surname>McCallion</surname> <given-names>AS</given-names></name><name><surname>Loeys</surname> <given-names>BL</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mutations in the TGF-β repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm</article-title><source>Nature Genetics</source><volume>44</volume><fpage>1249</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1038/ng.2421</pub-id><pub-id pub-id-type="pmid">23023332</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>P</given-names></name><name><surname>Lohkamp</surname> <given-names>B</given-names></name><name><surname>Scott</surname> <given-names>WG</given-names></name><name><surname>Cowtan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of <italic>coot</italic></article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname> <given-names>DJ</given-names></name><name><surname>Berger</surname> <given-names>P</given-names></name><name><surname>Schaffitzel</surname> <given-names>C</given-names></name><name><surname>Yamada</surname> <given-names>K</given-names></name><name><surname>Richmond</surname> <given-names>TJ</given-names></name><name><surname>Berger</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protein complex expression by using multigene baculoviral vectors</article-title><source>Nature Methods</source><volume>3</volume><fpage>1021</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1038/nmeth983</pub-id><pub-id pub-id-type="pmid">17117155</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname> <given-names>EM</given-names></name><name><surname>Loch</surname> <given-names>DC</given-names></name><name><surname>Habashi</surname> <given-names>JP</given-names></name><name><surname>Calderon</surname> <given-names>JF</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Bedja</surname> <given-names>D</given-names></name><name><surname>van Erp</surname> <given-names>C</given-names></name><name><surname>Gerber</surname> <given-names>EE</given-names></name><name><surname>Parker</surname> <given-names>SJ</given-names></name><name><surname>Sauls</surname> <given-names>K</given-names></name><name><surname>Judge</surname> <given-names>DP</given-names></name><name><surname>Cooke</surname> <given-names>SK</given-names></name><name><surname>Lindsay</surname> <given-names>ME</given-names></name><name><surname>Rouf</surname> <given-names>R</given-names></name><name><surname>Myers</surname> <given-names>L</given-names></name><name><surname>ap Rhys</surname> <given-names>CM</given-names></name><name><surname>Kent</surname> <given-names>KC</given-names></name><name><surname>Norris</surname> <given-names>RA</given-names></name><name><surname>Huso</surname> <given-names>DL</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>448</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1172/JCI69666</pub-id><pub-id pub-id-type="pmid">24355923</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glesby</surname> <given-names>MJ</given-names></name><name><surname>Pyeritz</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum</article-title><source>Jama</source><volume>262</volume><fpage>523</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1001/jama.1989.03430040095032</pub-id><pub-id pub-id-type="pmid">2739055</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greally</surname> <given-names>MT</given-names></name><name><surname>Carey</surname> <given-names>JC</given-names></name><name><surname>Milewicz</surname> <given-names>DM</given-names></name><name><surname>Hudgins</surname> <given-names>L</given-names></name><name><surname>Goldberg</surname> <given-names>RB</given-names></name><name><surname>Shprintzen</surname> <given-names>RJ</given-names></name><name><surname>Cousineau</surname> <given-names>AJ</given-names></name><name><surname>Smith</surname> <given-names>WL</given-names></name><name><surname>Judisch</surname> <given-names>GF</given-names></name><name><surname>Hanson</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Shprintzen-Goldberg syndrome: a clinical analysis</article-title><source>American Journal of Medical Genetics</source><volume>76</volume><fpage>202</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19980319)76:3&lt;202::AID-AJMG2&gt;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">9508238</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grönroos</surname> <given-names>E</given-names></name><name><surname>Kingston</surname> <given-names>IJ</given-names></name><name><surname>Ramachandran</surname> <given-names>A</given-names></name><name><surname>Randall</surname> <given-names>RA</given-names></name><name><surname>Vizán</surname> <given-names>P</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Transforming growth factor β inhibits bone morphogenetic protein-induced transcription through novel phosphorylated Smad1/5-Smad3 complexes</article-title><source>Molecular and Cellular Biology</source><volume>32</volume><fpage>2904</fpage><lpage>2916</lpage><pub-id pub-id-type="doi">10.1128/MCB.00231-12</pub-id><pub-id pub-id-type="pmid">22615489</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>Z</given-names></name><name><surname>Eils</surname> <given-names>R</given-names></name><name><surname>Schlesner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title><source>Bioinformatics</source><volume>32</volume><fpage>2847</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw313</pub-id><pub-id pub-id-type="pmid">27207943</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habashi</surname> <given-names>JP</given-names></name><name><surname>Judge</surname> <given-names>DP</given-names></name><name><surname>Holm</surname> <given-names>TM</given-names></name><name><surname>Cohn</surname> <given-names>RD</given-names></name><name><surname>Loeys</surname> <given-names>BL</given-names></name><name><surname>Cooper</surname> <given-names>TK</given-names></name><name><surname>Myers</surname> <given-names>L</given-names></name><name><surname>Klein</surname> <given-names>EC</given-names></name><name><surname>Liu</surname> <given-names>G</given-names></name><name><surname>Calvi</surname> <given-names>C</given-names></name><name><surname>Podowski</surname> <given-names>M</given-names></name><name><surname>Neptune</surname> <given-names>ER</given-names></name><name><surname>Halushka</surname> <given-names>MK</given-names></name><name><surname>Bedja</surname> <given-names>D</given-names></name><name><surname>Gabrielson</surname> <given-names>K</given-names></name><name><surname>Rifkin</surname> <given-names>DB</given-names></name><name><surname>Carta</surname> <given-names>L</given-names></name><name><surname>Ramirez</surname> <given-names>F</given-names></name><name><surname>Huso</surname> <given-names>DL</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of marfan syndrome</article-title><source>Science</source><volume>312</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1126/science.1124287</pub-id><pub-id pub-id-type="pmid">16601194</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holm</surname> <given-names>TM</given-names></name><name><surname>Habashi</surname> <given-names>JP</given-names></name><name><surname>Doyle</surname> <given-names>JJ</given-names></name><name><surname>Bedja</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>van Erp</surname> <given-names>C</given-names></name><name><surname>Lindsay</surname> <given-names>ME</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Schoenhoff</surname> <given-names>F</given-names></name><name><surname>Cohn</surname> <given-names>RD</given-names></name><name><surname>Loeys</surname> <given-names>BL</given-names></name><name><surname>Thomas</surname> <given-names>CJ</given-names></name><name><surname>Patnaik</surname> <given-names>S</given-names></name><name><surname>Marugan</surname> <given-names>JJ</given-names></name><name><surname>Judge</surname> <given-names>DP</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Noncanonical tgfβ signaling contributes to aortic aneurysm progression in marfan syndrome mice</article-title><source>Science</source><volume>332</volume><fpage>358</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1126/science.1192149</pub-id><pub-id pub-id-type="pmid">21493862</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horbelt</surname> <given-names>D</given-names></name><name><surname>Guo</surname> <given-names>G</given-names></name><name><surname>Robinson</surname> <given-names>PN</given-names></name><name><surname>Knaus</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and smad signaling activity</article-title><source>Journal of Cell Science</source><volume>123</volume><fpage>4340</fpage><lpage>4350</lpage><pub-id pub-id-type="doi">10.1242/jcs.074773</pub-id><pub-id pub-id-type="pmid">21098638</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inman</surname> <given-names>GJ</given-names></name><name><surname>Nicolás</surname> <given-names>FJ</given-names></name><name><surname>Callahan</surname> <given-names>JF</given-names></name><name><surname>Harling</surname> <given-names>JD</given-names></name><name><surname>Gaster</surname> <given-names>LM</given-names></name><name><surname>Reith</surname> <given-names>AD</given-names></name><name><surname>Laping</surname> <given-names>NJ</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7</article-title><source>Molecular Pharmacology</source><volume>62</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1124/mol.62.1.65</pub-id><pub-id pub-id-type="pmid">12065756</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname> <given-names>M</given-names></name><name><surname>Ding</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Mao</surname> <given-names>N</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Computational investigation of a ternary model of SnoN-SMAD3-SMAD4 complex</article-title><source>Computational Biology and Chemistry</source><volume>83</volume><elocation-id>107159</elocation-id><pub-id pub-id-type="doi">10.1016/j.compbiolchem.2019.107159</pub-id><pub-id pub-id-type="pmid">31743832</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaartinen</surname> <given-names>V</given-names></name><name><surname>Warburton</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Fibrillin controls TGF-β activation</article-title><source>Nature Genetics</source><volume>33</volume><fpage>331</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/ng0303-331</pub-id><pub-id pub-id-type="pmid">12610545</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>XDS</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id><pub-id pub-id-type="pmid">20124692</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korchynskyi</surname> <given-names>O</given-names></name><name><surname>ten Dijke</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>4883</fpage><lpage>4891</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111023200</pub-id><pub-id pub-id-type="pmid">11729207</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Scolan</surname> <given-names>E</given-names></name><name><surname>Zhu</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Bandyopadhyay</surname> <given-names>A</given-names></name><name><surname>Javelaud</surname> <given-names>D</given-names></name><name><surname>Mauviel</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Luo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transforming growth factor-beta suppresses the ability of ski to inhibit tumor metastasis by inducing its degradation</article-title><source>Cancer Research</source><volume>68</volume><fpage>3277</fpage><lpage>3285</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6793</pub-id><pub-id pub-id-type="pmid">18451154</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname> <given-names>L</given-names></name><name><surname>Howell</surname> <given-names>M</given-names></name><name><surname>Das</surname> <given-names>D</given-names></name><name><surname>Harkin</surname> <given-names>S</given-names></name><name><surname>Episkopou</surname> <given-names>V</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>6068</fpage><lpage>6083</lpage><pub-id pub-id-type="doi">10.1128/MCB.00664-07</pub-id><pub-id pub-id-type="pmid">17591695</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>Dewey</surname> <given-names>CN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>323</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-323</pub-id><pub-id pub-id-type="pmid">21816040</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebschner</surname> <given-names>D</given-names></name><name><surname>Afonine</surname> <given-names>PV</given-names></name><name><surname>Baker</surname> <given-names>ML</given-names></name><name><surname>Bunkóczi</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>VB</given-names></name><name><surname>Croll</surname> <given-names>TI</given-names></name><name><surname>Hintze</surname> <given-names>B</given-names></name><name><surname>Hung</surname> <given-names>LW</given-names></name><name><surname>Jain</surname> <given-names>S</given-names></name><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Moriarty</surname> <given-names>NW</given-names></name><name><surname>Oeffner</surname> <given-names>RD</given-names></name><name><surname>Poon</surname> <given-names>BK</given-names></name><name><surname>Prisant</surname> <given-names>MG</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name><name><surname>Richardson</surname> <given-names>JS</given-names></name><name><surname>Richardson</surname> <given-names>DC</given-names></name><name><surname>Sammito</surname> <given-names>MD</given-names></name><name><surname>Sobolev</surname> <given-names>OV</given-names></name><name><surname>Stockwell</surname> <given-names>DH</given-names></name><name><surname>Terwilliger</surname> <given-names>TC</given-names></name><name><surname>Urzhumtsev</surname> <given-names>AG</given-names></name><name><surname>Videau</surname> <given-names>LL</given-names></name><name><surname>Williams</surname> <given-names>CJ</given-names></name><name><surname>Adams</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in <italic>phenix</italic></article-title><source>Acta Crystallographica Section D Structural Biology</source><volume>75</volume><fpage>861</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1107/S2059798319011471</pub-id><pub-id pub-id-type="pmid">31588918</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsay</surname> <given-names>ME</given-names></name><name><surname>Schepers</surname> <given-names>D</given-names></name><name><surname>Bolar</surname> <given-names>NA</given-names></name><name><surname>Doyle</surname> <given-names>JJ</given-names></name><name><surname>Gallo</surname> <given-names>E</given-names></name><name><surname>Fert-Bober</surname> <given-names>J</given-names></name><name><surname>Kempers</surname> <given-names>MJ</given-names></name><name><surname>Fishman</surname> <given-names>EK</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Myers</surname> <given-names>L</given-names></name><name><surname>Bjeda</surname> <given-names>D</given-names></name><name><surname>Oswald</surname> <given-names>G</given-names></name><name><surname>Elias</surname> <given-names>AF</given-names></name><name><surname>Levy</surname> <given-names>HP</given-names></name><name><surname>Anderlid</surname> <given-names>BM</given-names></name><name><surname>Yang</surname> <given-names>MH</given-names></name><name><surname>Bongers</surname> <given-names>EM</given-names></name><name><surname>Timmermans</surname> <given-names>J</given-names></name><name><surname>Braverman</surname> <given-names>AC</given-names></name><name><surname>Canham</surname> <given-names>N</given-names></name><name><surname>Mortier</surname> <given-names>GR</given-names></name><name><surname>Brunner</surname> <given-names>HG</given-names></name><name><surname>Byers</surname> <given-names>PH</given-names></name><name><surname>Van Eyk</surname> <given-names>J</given-names></name><name><surname>Van Laer</surname> <given-names>L</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name><name><surname>Loeys</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm</article-title><source>Nature Genetics</source><volume>44</volume><fpage>922</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1038/ng.2349</pub-id><pub-id pub-id-type="pmid">22772368</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeys</surname> <given-names>BL</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Neptune</surname> <given-names>ER</given-names></name><name><surname>Judge</surname> <given-names>DP</given-names></name><name><surname>Podowski</surname> <given-names>M</given-names></name><name><surname>Holm</surname> <given-names>T</given-names></name><name><surname>Meyers</surname> <given-names>J</given-names></name><name><surname>Leitch</surname> <given-names>CC</given-names></name><name><surname>Katsanis</surname> <given-names>N</given-names></name><name><surname>Sharifi</surname> <given-names>N</given-names></name><name><surname>Xu</surname> <given-names>FL</given-names></name><name><surname>Myers</surname> <given-names>LA</given-names></name><name><surname>Spevak</surname> <given-names>PJ</given-names></name><name><surname>Cameron</surname> <given-names>DE</given-names></name><name><surname>De Backer</surname> <given-names>J</given-names></name><name><surname>Hellemans</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Davis</surname> <given-names>EC</given-names></name><name><surname>Webb</surname> <given-names>CL</given-names></name><name><surname>Kress</surname> <given-names>W</given-names></name><name><surname>Coucke</surname> <given-names>P</given-names></name><name><surname>Rifkin</surname> <given-names>DB</given-names></name><name><surname>De Paepe</surname> <given-names>AM</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2</article-title><source>Nature Genetics</source><volume>37</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1038/ng1511</pub-id><pub-id pub-id-type="pmid">15731757</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>K</given-names></name><name><surname>Stroschein</surname> <given-names>SL</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Martens</surname> <given-names>E</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The Ski oncoprotein interacts with the Smad proteins to repress TGFβ signaling</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>2196</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1101/gad.13.17.2196</pub-id><pub-id pub-id-type="pmid">10485843</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Ski and SnoN: negative regulators of TGF-β signaling</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>14</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2003.11.003</pub-id><pub-id pub-id-type="pmid">15108807</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacFarlane</surname> <given-names>EG</given-names></name><name><surname>Parker</surname> <given-names>SJ</given-names></name><name><surname>Shin</surname> <given-names>JY</given-names></name><name><surname>Kang</surname> <given-names>BE</given-names></name><name><surname>Ziegler</surname> <given-names>SG</given-names></name><name><surname>Creamer</surname> <given-names>TJ</given-names></name><name><surname>Bagirzadeh</surname> <given-names>R</given-names></name><name><surname>Bedja</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Calderon</surname> <given-names>JF</given-names></name><name><surname>Weissler</surname> <given-names>K</given-names></name><name><surname>Frischmeyer-Guerrerio</surname> <given-names>PA</given-names></name><name><surname>Lindsay</surname> <given-names>ME</given-names></name><name><surname>Habashi</surname> <given-names>JP</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lineage-specific events underlie aortic root aneurysm pathogenesis in Loeys-Dietz syndrome</article-title><source>Journal of Clinical Investigation</source><volume>129</volume><fpage>659</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1172/JCI123547</pub-id><pub-id pub-id-type="pmid">30614814</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>EMBnet.journal</source><volume>17</volume><fpage>10</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massagué</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TGFβ signalling in context</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>13</volume><fpage>616</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1038/nrm3434</pub-id><pub-id pub-id-type="pmid">22992590</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Winn</surname> <given-names>MD</given-names></name><name><surname>Storoni</surname> <given-names>LC</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title><italic>Phaser</italic> crystallographic software</article-title><source>Journal of Applied Crystallography</source><volume>40</volume><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id><pub-id pub-id-type="pmid">19461840</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>DSJ</given-names></name><name><surname>Bloxham</surname> <given-names>RD</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Gori</surname> <given-names>I</given-names></name><name><surname>Saunders</surname> <given-names>RE</given-names></name><name><surname>Das</surname> <given-names>D</given-names></name><name><surname>Chakravarty</surname> <given-names>P</given-names></name><name><surname>Howell</surname> <given-names>M</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The dynamics of TGF-β signaling are dictated by receptor trafficking via the ESCRT machinery</article-title><source>Cell Reports</source><volume>25</volume><fpage>1841</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.056</pub-id><pub-id pub-id-type="pmid">30428352</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>DSJ</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>TGF-β superfamily signalling</chapter-title><person-group person-group-type="editor"><name><surname>Bradshaw</surname> <given-names>R. A</given-names></name><name><surname>Stahl</surname> <given-names>P. D</given-names></name></person-group><source>Encyclopedia of Cell Biology</source><publisher-name>Elsevier</publisher-name><fpage>1</fpage><lpage>308</lpage></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname> <given-names>MS</given-names></name><name><surname>Lancaster</surname> <given-names>K</given-names></name><name><surname>Adedeji</surname> <given-names>AO</given-names></name><name><surname>Palanisamy</surname> <given-names>GS</given-names></name><name><surname>Dave</surname> <given-names>RA</given-names></name><name><surname>Zhong</surname> <given-names>F</given-names></name><name><surname>Holdren</surname> <given-names>MS</given-names></name><name><surname>Turley</surname> <given-names>SJ</given-names></name><name><surname>Liang</surname> <given-names>WC</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Meng</surname> <given-names>YG</given-names></name><name><surname>Vernes</surname> <given-names>JM</given-names></name><name><surname>Schutten</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A potent Pan-TGFβ neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys</article-title><source>Toxicological Sciences</source><volume>175</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfaa024</pub-id><pub-id pub-id-type="pmid">32077954</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazono</surname> <given-names>KI</given-names></name><name><surname>Moriwaki</surname> <given-names>S</given-names></name><name><surname>Ito</surname> <given-names>T</given-names></name><name><surname>Kurisaki</surname> <given-names>A</given-names></name><name><surname>Asashima</surname> <given-names>M</given-names></name><name><surname>Tanokura</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hydrophobic patches on SMAD2 and SMAD3 determine selective binding to cofactors</article-title><source>Science Signaling</source><volume>11</volume><elocation-id>eaao7227</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aao7227</pub-id><pub-id pub-id-type="pmid">29588413</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murshudov</surname> <given-names>GN</given-names></name><name><surname>Skubák</surname> <given-names>P</given-names></name><name><surname>Lebedev</surname> <given-names>AA</given-names></name><name><surname>Pannu</surname> <given-names>NS</given-names></name><name><surname>Steiner</surname> <given-names>RA</given-names></name><name><surname>Nicholls</surname> <given-names>RA</given-names></name><name><surname>Winn</surname> <given-names>MD</given-names></name><name><surname>Long</surname> <given-names>F</given-names></name><name><surname>Vagin</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>REFMAC5 for the refinement of macromolecular crystal structures</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>67</volume><fpage>355</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1107/S0907444911001314</pub-id><pub-id pub-id-type="pmid">21460454</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagano</surname> <given-names>Y</given-names></name><name><surname>Mavrakis</surname> <given-names>KJ</given-names></name><name><surname>Lee</surname> <given-names>KL</given-names></name><name><surname>Fujii</surname> <given-names>T</given-names></name><name><surname>Koinuma</surname> <given-names>D</given-names></name><name><surname>Sase</surname> <given-names>H</given-names></name><name><surname>Yuki</surname> <given-names>K</given-names></name><name><surname>Isogaya</surname> <given-names>K</given-names></name><name><surname>Saitoh</surname> <given-names>M</given-names></name><name><surname>Imamura</surname> <given-names>T</given-names></name><name><surname>Episkopou</surname> <given-names>V</given-names></name><name><surname>Miyazono</surname> <given-names>K</given-names></name><name><surname>Miyazawa</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-beta signaling</article-title><source>Journal of Biological Chemistry</source><volume>282</volume><fpage>20492</fpage><lpage>20501</lpage><pub-id pub-id-type="doi">10.1074/jbc.M701294200</pub-id><pub-id pub-id-type="pmid">17510063</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neptune</surname> <given-names>ER</given-names></name><name><surname>Frischmeyer</surname> <given-names>PA</given-names></name><name><surname>Arking</surname> <given-names>DE</given-names></name><name><surname>Myers</surname> <given-names>L</given-names></name><name><surname>Bunton</surname> <given-names>TE</given-names></name><name><surname>Gayraud</surname> <given-names>B</given-names></name><name><surname>Ramirez</surname> <given-names>F</given-names></name><name><surname>Sakai</surname> <given-names>LY</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome</article-title><source>Nature Genetics</source><volume>33</volume><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/ng1116</pub-id><pub-id pub-id-type="pmid">12598898</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolás</surname> <given-names>FJ</given-names></name><name><surname>De Bosscher</surname> <given-names>K</given-names></name><name><surname>Schmierer</surname> <given-names>B</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Analysis of smad nucleocytoplasmic shuttling in living cells</article-title><source>Journal of Cell Science</source><volume>117</volume><fpage>4113</fpage><lpage>4125</lpage><pub-id pub-id-type="doi">10.1242/jcs.01289</pub-id><pub-id pub-id-type="pmid">15280432</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname> <given-names>T</given-names></name><name><surname>Khan</surname> <given-names>MM</given-names></name><name><surname>Kaul</surname> <given-names>SC</given-names></name><name><surname>Dong</surname> <given-names>HD</given-names></name><name><surname>Wadhwa</surname> <given-names>R</given-names></name><name><surname>Colmenares</surname> <given-names>C</given-names></name><name><surname>Kohno</surname> <given-names>I</given-names></name><name><surname>Ishii</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>412</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1101/gad.13.4.412</pub-id><pub-id pub-id-type="pmid">10049357</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piek</surname> <given-names>E</given-names></name><name><surname>Ju</surname> <given-names>WJ</given-names></name><name><surname>Heyer</surname> <given-names>J</given-names></name><name><surname>Escalante-Alcalde</surname> <given-names>D</given-names></name><name><surname>Stewart</surname> <given-names>CL</given-names></name><name><surname>Weinstein</surname> <given-names>M</given-names></name><name><surname>Deng</surname> <given-names>C</given-names></name><name><surname>Kucherlapati</surname> <given-names>R</given-names></name><name><surname>Bottinger</surname> <given-names>EP</given-names></name><name><surname>Roberts</surname> <given-names>AB</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts</article-title><source>Journal of Biological Chemistry</source><volume>276</volume><fpage>19945</fpage><lpage>19953</lpage><pub-id pub-id-type="doi">10.1074/jbc.M102382200</pub-id><pub-id pub-id-type="pmid">11262418</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierreux</surname> <given-names>CE</given-names></name><name><surname>Nicolás</surname> <given-names>FJ</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Transforming growth factor beta-independent shuttling of Smad4 between the cytoplasm and nucleus</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>9041</fpage><lpage>9054</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.23.9041-9054.2000</pub-id><pub-id pub-id-type="pmid">11074002</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2009">2009</year><data-title>R: A language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname> <given-names>A</given-names></name><name><surname>Vizán</surname> <given-names>P</given-names></name><name><surname>Das</surname> <given-names>D</given-names></name><name><surname>Chakravarty</surname> <given-names>P</given-names></name><name><surname>Vogt</surname> <given-names>J</given-names></name><name><surname>Rogers</surname> <given-names>KW</given-names></name><name><surname>Müller</surname> <given-names>P</given-names></name><name><surname>Hinck</surname> <given-names>AP</given-names></name><name><surname>Sapkota</surname> <given-names>GP</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TGF-β uses a novel mode of receptor activation to phosphorylate SMAD1/5 and induce epithelial-to-mesenchymal transition</article-title><source>eLife</source><volume>7</volume><elocation-id>e31756</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.31756</pub-id><pub-id pub-id-type="pmid">29376829</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname> <given-names>F</given-names></name><name><surname>Sakai</surname> <given-names>LY</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name><name><surname>Rifkin</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Fibrillin microfibrils: multipurpose extracellular networks in organismal physiology</article-title><source>Physiological Genomics</source><volume>19</volume><fpage>151</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1152/physiolgenomics.00092.2004</pub-id><pub-id pub-id-type="pmid">15466717</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wright</surname> <given-names>J</given-names></name><name><surname>Agarwala</surname> <given-names>V</given-names></name><name><surname>Scott</surname> <given-names>DA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome engineering using the CRISPR-Cas9 system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randall</surname> <given-names>RA</given-names></name><name><surname>Germain</surname> <given-names>S</given-names></name><name><surname>Inman</surname> <given-names>GJ</given-names></name><name><surname>Bates</surname> <given-names>PA</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Different Smad2 partners bind a common hydrophobic pocket in Smad2 via a defined proline-rich motif</article-title><source>The EMBO Journal</source><volume>21</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1093/emboj/21.1.145</pub-id><pub-id pub-id-type="pmid">11782434</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randall</surname> <given-names>RA</given-names></name><name><surname>Howell</surname> <given-names>M</given-names></name><name><surname>Page</surname> <given-names>CS</given-names></name><name><surname>Daly</surname> <given-names>A</given-names></name><name><surname>Bates</surname> <given-names>PA</given-names></name><name><surname>Hill</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Recognition of phosphorylated-Smad2-containing complexes by a novel smad interaction motif</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>1106</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.3.1106-1121.2004</pub-id><pub-id pub-id-type="pmid">14729957</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rifkin</surname> <given-names>DB</given-names></name><name><surname>Rifkin</surname> <given-names>WJ</given-names></name><name><surname>Zilberberg</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LTBPs in biology and medicine: ltbp diseases</article-title><source>Matrix Biology</source><volume>71-72</volume><fpage>90</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2017.11.014</pub-id><pub-id pub-id-type="pmid">29217273</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname> <given-names>IB</given-names></name><name><surname>Horiguchi</surname> <given-names>M</given-names></name><name><surname>Zilberberg</surname> <given-names>L</given-names></name><name><surname>Dabovic</surname> <given-names>B</given-names></name><name><surname>Hadjiolova</surname> <given-names>K</given-names></name><name><surname>Rifkin</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Latent TGF-β-binding proteins</article-title><source>Matrix Biology</source><volume>47</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2015.05.005</pub-id><pub-id pub-id-type="pmid">25960419</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname> <given-names>IB</given-names></name><name><surname>Rifkin</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulation of the bioavailability of TGF-β and TGF-β-Related proteins</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>8</volume><elocation-id>a021907</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a021907</pub-id><pub-id pub-id-type="pmid">27252363</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepers</surname> <given-names>D</given-names></name><name><surname>Doyle</surname> <given-names>AJ</given-names></name><name><surname>Oswald</surname> <given-names>G</given-names></name><name><surname>Sparks</surname> <given-names>E</given-names></name><name><surname>Myers</surname> <given-names>L</given-names></name><name><surname>Willems</surname> <given-names>PJ</given-names></name><name><surname>Mansour</surname> <given-names>S</given-names></name><name><surname>Simpson</surname> <given-names>MA</given-names></name><name><surname>Frysira</surname> <given-names>H</given-names></name><name><surname>Maat-Kievit</surname> <given-names>A</given-names></name><name><surname>Van Minkelen</surname> <given-names>R</given-names></name><name><surname>Hoogeboom</surname> <given-names>JM</given-names></name><name><surname>Mortier</surname> <given-names>GR</given-names></name><name><surname>Titheradge</surname> <given-names>H</given-names></name><name><surname>Brueton</surname> <given-names>L</given-names></name><name><surname>Starr</surname> <given-names>L</given-names></name><name><surname>Stark</surname> <given-names>Z</given-names></name><name><surname>Ockeloen</surname> <given-names>C</given-names></name><name><surname>Lourenco</surname> <given-names>CM</given-names></name><name><surname>Blair</surname> <given-names>E</given-names></name><name><surname>Hobson</surname> <given-names>E</given-names></name><name><surname>Hurst</surname> <given-names>J</given-names></name><name><surname>Maystadt</surname> <given-names>I</given-names></name><name><surname>Destrée</surname> <given-names>A</given-names></name><name><surname>Girisha</surname> <given-names>KM</given-names></name><name><surname>Miller</surname> <given-names>M</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name><name><surname>Loeys</surname> <given-names>B</given-names></name><name><surname>Van Laer</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The SMAD-binding domain of SKI: a hotspot for de novo mutations causing Shprintzen-Goldberg syndrome</article-title><source>European Journal of Human Genetics</source><volume>23</volume><fpage>224</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2014.61</pub-id><pub-id pub-id-type="pmid">24736733</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepers</surname> <given-names>D</given-names></name><name><surname>Tortora</surname> <given-names>G</given-names></name><name><surname>Morisaki</surname> <given-names>H</given-names></name><name><surname>MacCarrick</surname> <given-names>G</given-names></name><name><surname>Lindsay</surname> <given-names>M</given-names></name><name><surname>Liang</surname> <given-names>D</given-names></name><name><surname>Mehta</surname> <given-names>SG</given-names></name><name><surname>Hague</surname> <given-names>J</given-names></name><name><surname>Verhagen</surname> <given-names>J</given-names></name><name><surname>van de Laar</surname> <given-names>I</given-names></name><name><surname>Wessels</surname> <given-names>M</given-names></name><name><surname>Detisch</surname> <given-names>Y</given-names></name><name><surname>van Haelst</surname> <given-names>M</given-names></name><name><surname>Baas</surname> <given-names>A</given-names></name><name><surname>Lichtenbelt</surname> <given-names>K</given-names></name><name><surname>Braun</surname> <given-names>K</given-names></name><name><surname>van der Linde</surname> <given-names>D</given-names></name><name><surname>Roos-Hesselink</surname> <given-names>J</given-names></name><name><surname>McGillivray</surname> <given-names>G</given-names></name><name><surname>Meester</surname> <given-names>J</given-names></name><name><surname>Maystadt</surname> <given-names>I</given-names></name><name><surname>Coucke</surname> <given-names>P</given-names></name><name><surname>El-Khoury</surname> <given-names>E</given-names></name><name><surname>Parkash</surname> <given-names>S</given-names></name><name><surname>Diness</surname> <given-names>B</given-names></name><name><surname>Risom</surname> <given-names>L</given-names></name><name><surname>Scurr</surname> <given-names>I</given-names></name><name><surname>Hilhorst-Hofstee</surname> <given-names>Y</given-names></name><name><surname>Morisaki</surname> <given-names>T</given-names></name><name><surname>Richer</surname> <given-names>J</given-names></name><name><surname>Désir</surname> <given-names>J</given-names></name><name><surname>Kempers</surname> <given-names>M</given-names></name><name><surname>Rideout</surname> <given-names>AL</given-names></name><name><surname>Horne</surname> <given-names>G</given-names></name><name><surname>Bennett</surname> <given-names>C</given-names></name><name><surname>Rahikkala</surname> <given-names>E</given-names></name><name><surname>Vandeweyer</surname> <given-names>G</given-names></name><name><surname>Alaerts</surname> <given-names>M</given-names></name><name><surname>Verstraeten</surname> <given-names>A</given-names></name><name><surname>Dietz</surname> <given-names>H</given-names></name><name><surname>Van Laer</surname> <given-names>L</given-names></name><name><surname>Loeys</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A mutation update on the LDS-associated genes <italic>TGFB2/3</italic> and <italic>SMAD2/3</italic></article-title><source>Human Mutation</source><volume>39</volume><fpage>621</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1002/humu.23407</pub-id><pub-id pub-id-type="pmid">29392890</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Hata</surname> <given-names>A</given-names></name><name><surname>Lo</surname> <given-names>RS</given-names></name><name><surname>Massagué</surname> <given-names>J</given-names></name><name><surname>Pavletich</surname> <given-names>NP</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>A structural basis for mutational inactivation of the tumour suppressor Smad4</article-title><source>Nature</source><volume>388</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/40431</pub-id><pub-id pub-id-type="pmid">9214508</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shprintzen</surname> <given-names>RJ</given-names></name><name><surname>Goldberg</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>A recurrent pattern syndrome of craniosynostosis associated with arachnodactyly and abdominal hernias</article-title><source>Journal of Craniofacial Genetics and Developmental Biology</source><volume>2</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">6182156</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stauber</surname> <given-names>AJ</given-names></name><name><surname>Credille</surname> <given-names>KM</given-names></name><name><surname>Truex</surname> <given-names>LL</given-names></name><name><surname>Ehlhardt</surname> <given-names>WJ</given-names></name><name><surname>Young</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nonclinical safety evaluation of a transforming growth factor β receptor IKinase inhibitor in Fischer 344 rats and beagle dogs</article-title><source>Journal of Clinical Toxicology</source><volume>4</volume><elocation-id>1000196</elocation-id><pub-id pub-id-type="doi">10.4172/2161-0495.196</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroschein</surname> <given-names>SL</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Luo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein</article-title><source>Science</source><volume>286</volume><fpage>771</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1126/science.286.5440.771</pub-id><pub-id pub-id-type="pmid">10531062</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Ng-Eaton</surname> <given-names>E</given-names></name><name><surname>Lodish</surname> <given-names>HF</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>SnoN and ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling</article-title><source>PNAS</source><volume>96</volume><fpage>12442</fpage><lpage>12447</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.22.12442</pub-id><pub-id pub-id-type="pmid">10535941</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokitou</surname> <given-names>F</given-names></name><name><surname>Nomura</surname> <given-names>T</given-names></name><name><surname>Khan</surname> <given-names>MM</given-names></name><name><surname>Kaul</surname> <given-names>SC</given-names></name><name><surname>Wadhwa</surname> <given-names>R</given-names></name><name><surname>Yasukawa</surname> <given-names>T</given-names></name><name><surname>Kohno</surname> <given-names>I</given-names></name><name><surname>Ishii</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Viral ski inhibits retinoblastoma protein (Rb)-mediated transcriptional repression in a dominant negative fashion</article-title><source>Journal of Biological Chemistry</source><volume>274</volume><fpage>4485</fpage><lpage>4488</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.8.4485</pub-id><pub-id pub-id-type="pmid">9988677</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueki</surname> <given-names>N</given-names></name><name><surname>Hayman</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Direct interaction of ski with either Smad3 or Smad4 is necessary and sufficient for Ski-mediated repression of transforming growth factor-beta signaling</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>32489</fpage><lpage>32492</lpage><pub-id pub-id-type="doi">10.1074/jbc.C300276200</pub-id><pub-id pub-id-type="pmid">12857746</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Laar</surname> <given-names>IM</given-names></name><name><surname>van der Linde</surname> <given-names>D</given-names></name><name><surname>Oei</surname> <given-names>EH</given-names></name><name><surname>Bos</surname> <given-names>PK</given-names></name><name><surname>Bessems</surname> <given-names>JH</given-names></name><name><surname>Bierma-Zeinstra</surname> <given-names>SM</given-names></name><name><surname>van Meer</surname> <given-names>BL</given-names></name><name><surname>Pals</surname> <given-names>G</given-names></name><name><surname>Oldenburg</surname> <given-names>RA</given-names></name><name><surname>Bekkers</surname> <given-names>JA</given-names></name><name><surname>Moelker</surname> <given-names>A</given-names></name><name><surname>de Graaf</surname> <given-names>BM</given-names></name><name><surname>Matyas</surname> <given-names>G</given-names></name><name><surname>Frohn-Mulder</surname> <given-names>IM</given-names></name><name><surname>Timmermans</surname> <given-names>J</given-names></name><name><surname>Hilhorst-Hofstee</surname> <given-names>Y</given-names></name><name><surname>Cobben</surname> <given-names>JM</given-names></name><name><surname>Bruggenwirth</surname> <given-names>HT</given-names></name><name><surname>van Laer</surname> <given-names>L</given-names></name><name><surname>Loeys</surname> <given-names>B</given-names></name><name><surname>De Backer</surname> <given-names>J</given-names></name><name><surname>Coucke</surname> <given-names>PJ</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name><name><surname>Willems</surname> <given-names>PJ</given-names></name><name><surname>Oostra</surname> <given-names>BA</given-names></name><name><surname>De Paepe</surname> <given-names>A</given-names></name><name><surname>Roos-Hesselink</surname> <given-names>JW</given-names></name><name><surname>Bertoli-Avella</surname> <given-names>AM</given-names></name><name><surname>Wessels</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome</article-title><source>Journal of Medical Genetics</source><volume>49</volume><fpage>47</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2011-100382</pub-id><pub-id pub-id-type="pmid">22167769</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verstraeten</surname> <given-names>A</given-names></name><name><surname>Alaerts</surname> <given-names>M</given-names></name><name><surname>Van Laer</surname> <given-names>L</given-names></name><name><surname>Loeys</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Marfan syndrome and related disorders: 25 years of gene discovery</article-title><source>Human Mutation</source><volume>37</volume><fpage>524</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1002/humu.22977</pub-id><pub-id pub-id-type="pmid">26919284</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walldén</surname> <given-names>K</given-names></name><name><surname>Nyman</surname> <given-names>T</given-names></name><name><surname>Hällberg</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SnoN stabilizes the SMAD3/SMAD4 protein complex</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>46370</elocation-id><pub-id pub-id-type="doi">10.1038/srep46370</pub-id><pub-id pub-id-type="pmid">28397834</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>H</given-names></name><name><surname>Hu</surname> <given-names>JH</given-names></name><name><surname>Angelov</surname> <given-names>SN</given-names></name><name><surname>Fox</surname> <given-names>K</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Enstrom</surname> <given-names>R</given-names></name><name><surname>Smith</surname> <given-names>A</given-names></name><name><surname>Dichek</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Aortopathy in a mouse model of marfan syndrome is not mediated by altered transforming growth factor β signaling</article-title><source>Journal of the American Heart Association</source><volume>6</volume><elocation-id>e004968</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.116.004968</pub-id><pub-id pub-id-type="pmid">28119285</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname> <given-names>JA</given-names></name><name><surname>Loeys</surname> <given-names>BL</given-names></name><name><surname>Nwakanma</surname> <given-names>LU</given-names></name><name><surname>Dietz</surname> <given-names>HC</given-names></name><name><surname>Spevak</surname> <given-names>PJ</given-names></name><name><surname>Patel</surname> <given-names>ND</given-names></name><name><surname>François</surname> <given-names>K</given-names></name><name><surname>DeBacker</surname> <given-names>J</given-names></name><name><surname>Gott</surname> <given-names>VL</given-names></name><name><surname>Vricella</surname> <given-names>LA</given-names></name><name><surname>Cameron</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Early surgical experience with Loeys-Dietz: a new syndrome of aggressive thoracic aortic aneurysm disease</article-title><source>The Annals of Thoracic Surgery</source><volume>83</volume><fpage>S757</fpage><lpage>S763</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2006.10.091</pub-id><pub-id pub-id-type="pmid">17257922</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname> <given-names>JJ</given-names></name><name><surname>Malakhova</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Joachimiak</surname> <given-names>A</given-names></name><name><surname>Hegde</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Crystal structure of the dachshund homology domain of human SKI</article-title><source>Structure</source><volume>12</volume><fpage>785</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1016/j.str.2004.02.035</pub-id><pub-id pub-id-type="pmid">15130471</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winn</surname> <given-names>MD</given-names></name><name><surname>Ballard</surname> <given-names>CC</given-names></name><name><surname>Cowtan</surname> <given-names>KD</given-names></name><name><surname>Dodson</surname> <given-names>EJ</given-names></name><name><surname>Emsley</surname> <given-names>P</given-names></name><name><surname>Evans</surname> <given-names>PR</given-names></name><name><surname>Keegan</surname> <given-names>RM</given-names></name><name><surname>Krissinel</surname> <given-names>EB</given-names></name><name><surname>Leslie</surname> <given-names>AG</given-names></name><name><surname>McCoy</surname> <given-names>A</given-names></name><name><surname>McNicholas</surname> <given-names>SJ</given-names></name><name><surname>Murshudov</surname> <given-names>GN</given-names></name><name><surname>Pannu</surname> <given-names>NS</given-names></name><name><surname>Potterton</surname> <given-names>EA</given-names></name><name><surname>Powell</surname> <given-names>HR</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name><name><surname>Vagin</surname> <given-names>A</given-names></name><name><surname>Wilson</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Overview of the CCP4 suite and current developments</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>67</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1107/S0907444910045749</pub-id><pub-id pub-id-type="pmid">21460441</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title><italic>xia2</italic> : an expert system for macromolecular crystallography data reduction</article-title><source>Journal of Applied Crystallography</source><volume>43</volume><fpage>186</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1107/S0021889809045701</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>C</given-names></name><name><surname>Rougier-Chapman</surname> <given-names>EM</given-names></name><name><surname>Frederick</surname> <given-names>JP</given-names></name><name><surname>Datto</surname> <given-names>MB</given-names></name><name><surname>Liberati</surname> <given-names>NT</given-names></name><name><surname>Li</surname> <given-names>JM</given-names></name><name><surname>Wang</surname> <given-names>XF</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta</article-title><source>Molecular and Cellular Biology</source><volume>19</volume><fpage>1821</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1128/MCB.19.3.1821</pub-id><pub-id pub-id-type="pmid">10022869</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>YG</given-names></name><name><surname>Ozdamar</surname> <given-names>B</given-names></name><name><surname>Gyuricza</surname> <given-names>CA</given-names></name><name><surname>Chong</surname> <given-names>PA</given-names></name><name><surname>Wrana</surname> <given-names>JL</given-names></name><name><surname>Massagué</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Structural basis of Smad2 recognition by the smad anchor for receptor activation</article-title><source>Science</source><volume>287</volume><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1126/science.287.5450.92</pub-id><pub-id pub-id-type="pmid">10615055</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>JW</given-names></name><name><surname>Hu</surname> <given-names>M</given-names></name><name><surname>Chai</surname> <given-names>J</given-names></name><name><surname>Seoane</surname> <given-names>J</given-names></name><name><surname>Huse</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Rigotti</surname> <given-names>DJ</given-names></name><name><surname>Kyin</surname> <given-names>S</given-names></name><name><surname>Muir</surname> <given-names>TW</given-names></name><name><surname>Fairman</surname> <given-names>R</given-names></name><name><surname>Massagué</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Crystal structure of a phosphorylated Smad2. recognition of phosphoserine by the MH2 domain and insights on smad function in TGF-β signaling</article-title><source>Molecular Cell</source><volume>8</volume><fpage>1277</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(01)00421-x</pub-id><pub-id pub-id-type="pmid">11779503</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>JW</given-names></name><name><surname>Krawitz</surname> <given-names>AR</given-names></name><name><surname>Chai</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Luo</surname> <given-names>K</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Structural mechanism of Smad4 recognition by the nuclear oncoprotein ski: insights on Ski-mediated repression of TGF-β signaling</article-title><source>Cell</source><volume>111</volume><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)01006-1</pub-id><pub-id pub-id-type="pmid">12419246</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>JF</given-names></name><name><surname>Yang</surname> <given-names>YF</given-names></name><name><surname>Tan</surname> <given-names>ZP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>576 kb deletion in 1p36.33-p36.32 containing SKI is associated with limb malformation, congenital heart disease and epilepsy</article-title><source>Gene</source><volume>528</volume><fpage>352</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2013.07.024</pub-id><pub-id pub-id-type="pmid">23892090</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><boxed-text><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) <break/>or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HaCaT</td><td valign="top">Francis Crick Institute <break/>Cell Services</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0038">CVCL_0038</ext-link></td><td valign="top">Keratinocytes (immortalized adult)</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T</td><td valign="top">Francis Crick Institute <break/>Cell Services</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link></td><td valign="top">Embryonic kidney cells (normal)</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Dermal fibroblasts <break/>(normal, adult)</td><td valign="top">David Abraham, UCL, UK</td><td valign="top"/><td valign="top">Primary cells, male</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Dermal fibroblasts <break/>(carrying heterozygous <break/>mutation L32V SKI)</td><td valign="top"><xref ref-type="bibr" rid="bib8">Carmignac et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/23103230">23103230</ext-link></td><td valign="top"/><td valign="top">Primary cells, female</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Dermal fibroblasts <break/>(carrying heterozygous <break/>mutation ΔS94-97 SKI)</td><td valign="top"><xref ref-type="bibr" rid="bib8">Carmignac et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/23103230">23103230</ext-link></td><td valign="top"/><td valign="top">Primary cells, male</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HaCaT S4 KO #1; <break/>HaCaT S4 KO #2; <break/>HaCaT S4 KO #3; <break/>HaCaT S4 KO #4</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Keratinocytes in which SMAD4 <break/>is deleted by CRISPR/Cas9 <break/>technology</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T S2 KO #1; <break/>HEK293T S2 KO #2</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Embryonic kidney cells in which <break/>SMAD2 is deleted by <break/>CRISPR/Cas9 technology</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T S3 KO #1; <break/>HEK293T S3 KO #2</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Embryonic kidney cells in which <break/>SMAD3 is deleted by <break/>CRISPR/Cas9 technology</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T S2/S3 dKO #1; <break/>HEK293T S2/S3 dKO #2</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Embryonic kidney cells in which <break/>SMAD2 and SMAD3 are deleted <break/>simultaneously by <break/>CRISPR/Cas9 technology</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T S4 KO #1; <break/>HEK293T S4 KO #2</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Embryonic kidney cells in which <break/>SMAD4 is deleted by <break/>CRISPR/Cas9 technology</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T P35S SKI #1; <break/>HEK293T P35S SKI #2; <break/>HEK293T P35S SKI #3; <break/>HEK293T P35S SKI #4</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Embryonic kidney cells in which <break/>the P35S SKI mutation is <break/>introduced by <break/>CRISPR/Cas9 technology</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T <break/>CAGA<sub>12</sub>-Luciferase/Renilla</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Embryonic kidney cells in which <break/>the CAGA<sub>12</sub>-Luciferase and <break/>TK-Renilla reporters <break/>are stably expressed</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T <break/>BRE-Luciferase/Renilla</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Embryonic kidney cells in which <break/>the BRE-Luciferase and TK-Renilla <break/>reporters are stably expressed</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T P35S SKI <break/>CAGA<sub>12</sub> Luciferase/Renilla #2; <break/>HEK293T P35S SKI <break/>CAGA<sub>12</sub> Luciferase/Renilla #3</td><td valign="top">This paper</td><td valign="top"/><td valign="top">HEK293T P35S SKI clones 2 and 3 in <break/>which the CAGA<sub>12</sub>-Luciferase and <break/>TK-Renilla reporters are <break/>stably expressed</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HEK293T P35S SKI <break/>BRE-Luciferase/Renilla #2; <break/>HEK293T P35S SKI <break/>BRE-Luciferase/Renilla #3</td><td valign="top">This paper</td><td valign="top"/><td valign="top">HEK293T P35S SKI clones 2 and 3 in <break/>which the BRE-Luciferase and <break/>TK-Renilla reporters are <break/>stably expressed</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HaCaT S4 KO EGFP</td><td valign="top">This paper</td><td valign="top"/><td valign="top">HaCaT SMAD4 KO clone 2 cells <break/>stably expressing EGFP</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HaCaT SMAD4 KO rescue <break/>EGFP-SMAD4 WT</td><td valign="top">This paper</td><td valign="top"/><td valign="top">HaCaT SMAD4 KO clone 2 cells stably <break/>expressing EGFP-SMAD4 WT</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HaCaT SMAD4 KO rescue <break/>EGFP-SMAD4 D351H</td><td valign="top">This paper</td><td valign="top"/><td valign="top">HaCaT SMAD4 KO clone 2 cells stably <break/>expressing EGFP-SMAD4 D351H</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HaCaT SMAD4 KO rescue <break/>EGFP-SMAD4 D537Y</td><td valign="top">This paper</td><td valign="top"/><td valign="top">HaCaT SMAD4 KO clone 2 cells stably <break/>expressing EGFP-SMAD4 D537Y</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HaCaT SMAD4 KO <break/>rescue <break/>EGFP-SMAD4 A433E</td><td valign="top">This paper</td><td valign="top"/><td valign="top">HaCaT SMAD4 KO clone 2 cells stably <break/>expressing EGFP-SMAD4 A433E</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">HaCaT SMAD4 KO <break/>rescue <break/>EGFP-SMAD4 I435Y</td><td valign="top">This paper</td><td valign="top"/><td valign="top">HaCaT SMAD4 KO clone 2 cells stably <break/>expressing EGFP-SMAD4 I435Y</td></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top">MEF SMAD2<sup>Δex2</sup></td><td valign="top"><xref ref-type="bibr" rid="bib57">Piek et al., 2001</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/11262418">11262418</ext-link></td><td valign="top"/><td valign="top">Mouse embryo-derived fibroblasts <break/>carrying the homozygous <break/>null allele <italic>Smad2<sup>ex2</sup></italic></td></tr><tr><td valign="top">Cell line <break/>(<italic>Spodoptera frugiperda</italic>)</td><td valign="top">Sf21</td><td valign="top"><xref ref-type="bibr" rid="bib21">Fitzgerald et al., 2006</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/17117155">17117155</ext-link></td><td valign="top"/><td valign="top">Insect cells used to express <break/>recombinant proteins</td></tr><tr><td valign="top">Transfected construct</td><td valign="top">pGFP-C1</td><td valign="top">VectorBuilder</td><td valign="top">Clontech, <break/>Cat# 6084–1</td><td valign="top">Construct used to make HaCaT <break/>SMAD4 KO stably expressing EGFP</td></tr><tr><td valign="top">Transfected <break/>construct (human)</td><td valign="top">pEGFP-SMAD4 WT</td><td valign="top"><xref ref-type="bibr" rid="bib55">Nicolás et al., 2004</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/15280432">15280432</ext-link></td><td valign="top"/><td valign="top">Construct used to make HaCaT <break/>SMAD4 KO stably expressing <break/>EGFP SMAD4 WT</td></tr><tr><td valign="top">Transfected <break/>construct (human)</td><td valign="top">pEGFP-SMAD4 D351H</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Construct used to make HaCaT <break/>SMAD4 KO stably expressing <break/>EGFP-SMAD4 D351H</td></tr><tr><td valign="top">Transfected <break/>construct (human)</td><td valign="top">pEGFP-SMAD4 D537Y</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Construct used to make HaCaT <break/>SMAD4 KO stably expressing <break/>EGFP-SMAD4 D537Y</td></tr><tr><td valign="top">Transfected <break/>construct (human)</td><td valign="top">pEGFP-SMAD4 A433E</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Construct used to make HaCaT <break/>SMAD4 KO stably expressing <break/>EGFP-SMAD4 A433E</td></tr><tr><td valign="top">Transfected <break/>construct (human)</td><td valign="top">pEGFP-SMAD4 I435Y</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Construct used to make HaCaT <break/>SMAD4 KO stably expressing <break/>EGFP-SMAD4 I435Y</td></tr><tr><td valign="top">Transfected construct</td><td valign="top">pRL-TK Vector</td><td valign="top">Promega</td><td valign="top">Cat# E2241</td><td valign="top">Construct used to make HEK <break/>293T cells stably expressing <break/>TK Renilla</td></tr><tr><td valign="top">Transfected construct</td><td valign="top">pGL3-BRE-Luc</td><td valign="top"><xref ref-type="bibr" rid="bib34">Korchynskyi and ten Dijke, 2002</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/11729207">11729207</ext-link></td><td valign="top">Addgene <break/>Cat# 45126</td><td valign="top">Construct used to make HEK <break/>293T cells stably expressing <break/>Luciferase under control <break/>of the BRE</td></tr><tr><td valign="top">Transfected construct</td><td valign="top">pGL3 CAGA<sub>12</sub>-Luc</td><td valign="top"><xref ref-type="bibr" rid="bib15">Dennler et al., 1998</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/9606191">9606191</ext-link></td><td valign="top"/><td valign="top">Construct used to make HEK <break/>293T cells stably expressing <break/>Luciferase under control of <break/>the CAGA<sub>12</sub> sequence</td></tr><tr><td valign="top">Transfected construct</td><td valign="top">pSUPER.retro.puro</td><td valign="top">OligoEngine</td><td valign="top">Cat# VEC-pRT-0002</td><td valign="top">Construct used to express <break/>resistance to puromycin in order <break/>to make stable cell lines</td></tr><tr><td valign="top">Transfected construct</td><td valign="top">pSpCas9(BB)−2A-GFP <break/>(PX458)</td><td valign="top"><xref ref-type="bibr" rid="bib62">Ran et al., 2013</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/24157548">24157548</ext-link></td><td valign="top">Addgene Cat# 48138</td><td valign="top">Different oligonucleotides <break/>corresponding to gRNAs have <break/>been cloned into this plasmid <break/>in order to make several different <break/>CRISPR/Cas9 knockout cell lines.</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-phosphorylated <break/>SMAD2 <break/>(Rabbit monoclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 3108; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_490941">AB_490941</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-SMAD2/3 <break/>(mouse monoclonal)</td><td valign="top">BD Biosciences</td><td valign="top">Cat# 610843; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_398162">AB_398162</ext-link></td><td valign="top">IF (1:500) <break/>WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-phospho-SMAD3 <break/>(rabbit monoclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 9520; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2193207">AB_2193207</ext-link></td><td valign="top">WB (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-SMAD4 (B-8) <break/>(mouse monoclonal)</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-7966; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_627905">AB_627905</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-SMAD3 <break/>(Rabbit monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# 40854; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_777979">AB_777979</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-FLAG DYKDDDDK <break/>Tag (L5) <break/>(Rat monoclonal)</td><td valign="top">Thermo Fisher</td><td valign="top">Cat# MA1-142, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2536846">AB_2536846</ext-link></td><td valign="top">IP (5 µg) <break/>WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-MCM6 (C-20) <break/>(Goat polyclonal)</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-9843; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2142543">AB_2142543</ext-link></td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti MCM6 (H-8) <break/>(Mouse monoclonal)</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-393618 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2885187">AB_2885187</ext-link></td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Tubulin <break/>(Rat monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab6160; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_305328">AB_305328</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-SKI <break/>(Rabbit Polyclonal)</td><td valign="top">GeneTex</td><td valign="top">Cat# GTX133764 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2885186">AB_2885186</ext-link></td><td valign="top">IP (5 µg) <break/>WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-GFP <break/>(Goat polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab6673, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_305643">AB_305643</ext-link></td><td valign="top">IF (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti SKIL (SnoN) <break/>(H-317) <break/>(Rabbit polyclonal)</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-9141, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_671124">AB_671124</ext-link></td><td valign="top">WB (1:1000) <break/>IF (1:1000) <break/>Flow cytometry (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Goat IgG <break/>(H+L) Cross-adsorbed <break/>secondary antibody, <break/>Alexa Fluor 546</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# A-11056, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534103">AB_2534103</ext-link></td><td valign="top">IF (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">Anti-Rabbit Alexa Fluor 594</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# A-21244; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10562581">AB_10562581</ext-link></td><td valign="top">IF (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Rabbit Alexa Fluor 647</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# A-21244, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2535812">AB_2535812</ext-link></td><td valign="top">Flow cytometry (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-rabbit HRP</td><td valign="top">Dako</td><td valign="top">Cat# P0448; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617138">AB_2617138</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-mouse HRP</td><td valign="top">Dako</td><td valign="top">Cat#P0447; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617137">AB_2617137</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-rat HRP</td><td valign="top">Jackson Lab</td><td valign="top">Cat#712-035-153; <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2340639">AB_2340639</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit anti-goat HRP</td><td valign="top">Dako</td><td valign="top">Cat# P0449, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617143">AB_2617143</ext-link></td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pEF-FLAG-SKIL <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Transient transfection in <break/>HEK293T cells to <break/>express FLAG SKIL WT</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FLAG SKIL <break/>G103V (SKIL ΔS2/S3) <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Transient transfection in <break/>HEK293T cells to <break/>express FLAG SKIL G103V</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">FLAG SKIL R314A, <break/>T315A, H317A, <break/>W318E (SKIL ΔS4) <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Transient transfection in <break/>HEK293T cells to express <break/>FLAG SKIL R314A, <break/>T315A, H317A, W318E</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pFast Dual <break/>ALK5* GST-MH2-hSMAD2 <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Used to express recombinant <break/>proteins in insect cells</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pFastDual <break/>ALK5*/GST-hSMAD3 <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Used to express recombinant <break/>proteins in insect cells</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pBacPAK-SMAD4 <break/>(plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Used to express recombinant <break/>proteins in insect cells</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD4_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CACCGACAACTCGTTCGTAGTGATA</named-content> <break/>CRISPR/Cas9-mediated knockout <break/>guide, forward oligo 1</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD4_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">AAACTATCACTACGAACGAGTTGTC</named-content> <break/>CRISPR/Cas9 mediated knockout <break/>guide, reverse oligo 1</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD4_F2</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CACCGTGAGTATGCATAAGCGACGA</named-content> <break/>CRISPR/Cas9 mediated knockout <break/>guide, forward oligo 2</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD4_R2</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">AAACTCGTCGCTTATGCATACTCAC</named-content> <break/>CRISPR/Cas9 mediated knockout <break/>guide, reverse oligo 2</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD2 _F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CACCGCTATCGAACACCAAAATGC</named-content> <break/>CRISPR/Cas9 mediated knockout <break/>guide, forward oligo</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD2 _R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">AAACGCATTTTGGTGTTCGATAGC</named-content> <break/>CRISPR/Cas9 mediated knockout <break/>guide, reverse oligo</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD3_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CACCGGAATGTCTCCCCGACGCGC</named-content> <break/>CRISPR/Cas9 mediated knockout <break/>guide, forward oligo</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD3_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">AAACGCGCGTCGGGGAGACATTCC</named-content> <break/>CRISPR/Cas9 mediated knockout <break/>guide, reverse oligo</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKI_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CACCGCAGCGCGCCGAGAAAGCGGC</named-content> <break/>CRISPR/Cas9 mediated knockin <break/>guide, forward oligo</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKI_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">AAACGCCGCTTTCTCGGCGCGCTGC</named-content> <break/>CRISPR/Cas9 mediated knockin <break/>guide, reverse oligo</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKI</italic>_ssODN</td><td valign="top">This paper</td><td valign="top"/><td valign="top">G*C*<named-content content-type="sequence">AGTTCCACCTGAGCTCCATGAGC</named-content> <break/><named-content content-type="sequence">TCGCTGGGAGGATCCGCCGCTTTCTC</named-content> <break/><named-content content-type="sequence">GGCGCGCTGGGCGCAGGAGGCCTA</named-content> <break/><named-content content-type="sequence">CAAGAAGGAGAGCGCCAAGGAGGCG</named-content> <break/><named-content content-type="sequence">GGCGCGGCCGCGGTGCCG</named-content>*G*C <break/>Repair template</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKI_R2</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">GCCCATGACTTTGAGGATCTCC</named-content> <break/>Universal reverse primer for <break/>clone screening</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKI_F2</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">ATGAGCTCGCTGGGCGGCCCG</named-content> <break/>WT SKI forward primer <break/>for clone screening</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKI_F3</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">ATGAGCTCGCTGGGAGGATCC</named-content> <break/>P35S SKI forward primer <break/>for clone screening</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Biotinylated WT <italic>cJUN</italic> <break/>SBE oligonucleotide (top)</td><td valign="top"><xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/17591695">17591695</ext-link></td><td valign="top"/><td valign="top">5′-Biotin- <break/><named-content content-type="sequence">GGAGGTGCGCGGAGTCAGG</named-content> <break/><named-content content-type="sequence">CAGACAGACAGACACAGCCA</named-content> <break/><named-content content-type="sequence">GCCAGCCAGGTCGGCA</named-content> <break/>DNAP oligo - Top</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">WT cJUN SBE <break/>oligonucleotide (bottom)</td><td valign="top"><xref ref-type="bibr" rid="bib36">Levy et al., 2007</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/17591695">17591695</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">TGCCGACCTGGCTGGCTGGC</named-content> <break/><named-content content-type="sequence">TGTGTCTGTCTGTCTGCCTG</named-content> <break/><named-content content-type="sequence">ACTCCGCGCACCTCC</named-content> <break/>DNAP oligo - Bottom</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Biotinylated MUT <italic>cJUN</italic> <break/>SBE oligonucleotide (top)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">5′-biotin- <break/><named-content content-type="sequence">GGATTTGCTAATGATATAGT</named-content> <break/><named-content content-type="sequence">AATATATATATATACATATAT</named-content> <break/><named-content content-type="sequence">ATATATTGATCTTCA</named-content> <break/>Mutated DNAP oligo -Top</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">MUT <italic>cJUN</italic> <break/>SBE oligonucleotide (bottom)</td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">TGAAGATCAATATATATATAT</named-content> <break/><named-content content-type="sequence">GTATATATATATATTACTAT</named-content> <break/><named-content content-type="sequence">ATCATTAGCAAATCC</named-content> <break/>Mutated DNAP oligo -Bottom</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">MUT <italic>cJUN</italic> SBE <break/>oligo-nucleotide (top)</td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">GGATTTGCTAATGATATAGTA</named-content> <break/><named-content content-type="sequence">ATATATATATATACATATAT</named-content> <break/><named-content content-type="sequence">ATATATTGATCTTCA</named-content> <break/>Competitor mutant oligo - Top</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">MUT <italic>cJUN</italic> SBE <break/>oligo-nucleotide (bottom)</td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">TGAAGATCAATATATATATATG</named-content> <break/><named-content content-type="sequence">TATATATATATATTACTATA</named-content> <break/><named-content content-type="sequence">TCATTAGCAAATCC</named-content> <break/>Competitor mutant <break/>oligo – bottom</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>GAPDH_F1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib25">Grönroos et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22615489">22615489</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">CTTCAACAGCGACACCCACT</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>GAPDH_R1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib25">Grönroos et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22615489">22615489</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">GTGGTCCAGGGGTCTTACTC</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD7_F1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib25">Grönroos et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22615489">22615489</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">CTTAGCCGACTCTGCGAACT</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD7_R1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib25">Grönroos et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22615489">22615489</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">CCAGGCTCCAGAAGAAGTTG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKIL_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CTGGGGCTTTGAATCAGCTA</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKIL_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CATGGTCACCTTCCTGCTTT</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SERPINE1_F1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib25">Grönroos et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22615489">22615489</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">TGATGGCTCAGACCAACAAG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SERPINE1_R1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib25">Grönroos et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22615489">22615489</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">GTTGGTGAGGGCAGAGAGAG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>JUNB_F1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib60">Ramachandran et al., 2018</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29376829">29376829</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">ATACACAGCTACGGGATACGG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>JUNB_R1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib60">Ramachandran et al., 2018</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29376829">29376829</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">GCTCGGTTTCAGGAGTTTGT</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>ID1_F1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib60">Ramachandran et al., 2018</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29376829">29376829</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">GCCGAGGCGGCATGCGTTC</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>ID1_R1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib60">Ramachandran et al., 2018</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29376829">29376829</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">CTTGCCCCCTGGATGGCTGG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>ID3_F1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib25">Grönroos et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22615489">22615489</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">GGCCCCCACCTTCCCATCC</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>ID3_R1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib25">Grönroos et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22615489">22615489</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">GCCAGCACCTGCGTTCTGGAG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>CDKN1A_F1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib48">Miller et al., 2018</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/30428352">30428352</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">ACTCTCAGGGTCGAAAACGG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>CDKN1A_R1</italic></td><td valign="top"><xref ref-type="bibr" rid="bib48">Miller et al., 2018</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/30428352">30428352</ext-link></td><td valign="top"/><td valign="top"><named-content content-type="sequence">ATGTAGAGCGGGCCTTTGAG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>ISLR2_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">AGTCGGCGAATATTGGGAGC</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>ISLR2_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">ATGATCCGGCCACTCCTAGA</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>CALB2_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">ATGGCAAATTGGGCCTCTCA</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>CALB2_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">GGTCAGCTTCATGCCCTGAAAT</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SOX11_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">AGCGGAGGAGGTTTTCAGTG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SOX11_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">TTCCATTCGGTCTCGCCAAA</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>ITGB6_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">TGCGACCATCAGTGAAGAAG</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>ITGB6_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">GACAACCCCGATGAGAAGAA</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>HEY1_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">GCTTTTGAGAAGCAGGGATCT</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>HEY1_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">GATAACGCGCAACTTCTGCC</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>COL7A1_F1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CAAGGGGGACATGGGTGAAC</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>COL7A1_R1</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CGGATACCAGGCACTCCATC</named-content> <break/>PCR primer</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD4_F3</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">GTTCATAAGATCTACCCAAGTG</named-content> <break/><named-content content-type="sequence">AATATATAAAGGTCTTTGATTTG</named-content> <break/>PCR primer for cloning, <break/>forward primer carrying <break/>the mutation A433E</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD4_R3</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">ACGCAAATCAAAGACCTTTATA</named-content> <break/><named-content content-type="sequence">TATTCACTTGGGTAGATCTTATG</named-content> <break/>PCR primer for cloning, <break/>reverse primer carrying <break/>the mutation A433E</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD4_F4</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">AAGATCTACCCAAGTGCATATT</named-content> <break/><named-content content-type="sequence">ACAAGGTCTTTGATTTGCGTCAG</named-content> <break/>PCR primer for cloning, <break/>forward primer carrying <break/>the mutation I435Y</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SMAD4_R4</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CTGACGCAAATCAAAGACCTTGT</named-content> <break/><named-content content-type="sequence">AATATGCACTTGGGTAGATCTT</named-content> <break/>PCR primer for cloning, <break/>reverse primer carrying <break/>the mutation I435Y</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKIL_F2</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">CAGAGCTCGCTGGGTGTA</named-content> <break/><named-content content-type="sequence">CCAGCAGCATTTTC</named-content> <break/>PCR primer for cloning, <break/>forward primer carrying <break/>the mutation G103V</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>SKIL_R2</italic></td><td valign="top">This paper</td><td valign="top"/><td valign="top"><named-content content-type="sequence">GAAAATGCTGCTGGTAC</named-content> <break/><named-content content-type="sequence">ACCCAGCGAGCTCTG</named-content> <break/>PCR primer for cloning, <break/>reverse primer carrying <break/>the mutation G103V</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI peptide A</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid- <break/>FQPHPGLQKTLEQFHLSSMSS <break/>LGGPAAFSARWAQEAYKKES</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI peptide B</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid- <break/>FQPHPGLQKTLEQFHLS <break/>SMSSLGGPAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI peptide C</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid- <break/>GLQKTLEQFHLSSMSSLG <break/>GPAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI peptide D</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid- <break/>TLEQFHLSSMSSLGG <break/>PAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI peptide E</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid- <break/>TLEQFHLSSMSSLGGPA <break/>AFSARWAQEAYK</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI L21R</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid- <break/>FQPHPGLQKTREQFHLSS <break/>MSSLGGPAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI S28T</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid- <break/>FQPHPGLQKTLEQFHLS <break/>TMSSLGGPAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI S31L</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid- <break/>FQPHPGLQKTLEQFHLS <break/>SMSLLGGPAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI L32P</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid- <break/>FQPHPGLQKTLEQFHLS <break/>SMSSPGGPAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI G34D</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid – <break/>FQPHPGLQKTLEQFHLSS <break/>MSSLGDPAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI P35S</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid – <break/>FQPHPGLQKTLEQFHLSS <break/>MSSLGGSAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKIL WT</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid – <break/>LHLNPSLKHTLAQFHLSSQSS <break/>LGGPAAFSARHSQESMSPTV</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKIL L90R</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid – <break/>LHLNPSLKHTRAQFHLSSQS <break/>SLGGPAAFSARHSQESMSPTV</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKIL S100L</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid - <break/>LHLNPSLKHTLAQFHLSSQS <break/>LLGGPAAFSARHSQESMSPTV</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKIL G103D</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid - <break/>LHLNPSLKHTLAQFHLSSQSS <break/>LGDPAAFSARHSQESMSPTV</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKIL P104S</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Biotin-aminohexanoic <break/>acid - <break/>LHLNPSLKHTLAQFHLSSQSS <break/>LGGSAAFSARHSQESMSPTV</td></tr><tr><td valign="top">Peptide, <break/>recombinant protein</td><td valign="top">SKI WT</td><td valign="top">This paper</td><td valign="top"/><td valign="top">FQPHPGLQKTLEQFHLSSMSS <break/>LGGPAAFSARWAQE</td></tr><tr><td valign="top">Peptide, <break/>recombinant <break/>protein</td><td valign="top">Human recombinant TGF-β1</td><td valign="top">Peprotech</td><td valign="top">Cat# 100–21</td><td valign="top"/></tr><tr><td valign="top">Peptide, <break/>recombinant <break/>protein</td><td valign="top">Human recombinant BMP4</td><td valign="top">Peprotech</td><td valign="top">Cat# 120-05ET</td><td valign="top"/></tr><tr><td valign="top">Peptide, <break/>recombinant <break/>protein</td><td valign="top">Human recombinant Activin A</td><td valign="top">Peprotech</td><td valign="top">Cat# 120–14</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">PowerUp SYBR <break/>Green Master Mix</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# A25742</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Quickextract DNA <break/>extraction solution</td><td valign="top">Lucigen</td><td valign="top">Cat# QE09050</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Dual-Glo Luciferase <break/>Assay System</td><td valign="top">Promega</td><td valign="top">Cat# E2920</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Fugene 6 transfection <break/>reagent</td><td valign="top">Promega</td><td valign="top">Cat# E2691</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Superdex 200 10/300 <break/>size exclusion column</td><td valign="top">Cytiva</td><td valign="top">Cat# 28990944</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Streptavidin (SA) Biosensors</td><td valign="top">ForteBio</td><td valign="top">Cat# 18–5019</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Glutathione 4B Sepharose</td><td valign="top">Cytiva</td><td valign="top">Cat# 17075601</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Pierce NeutrAvidin Agarose</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 29200</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">GFP-Trap Agarose (IP)</td><td valign="top">Cromotek</td><td valign="top">Cat# gta-20</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Protein G <break/>Sepharose, Fast Flow</td><td valign="top">Sigma–Aldrich</td><td valign="top">Cat# P3296</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">cOmplete, EDTA-free <break/>Protease Inhibitor Cocktail</td><td valign="top">Sigma–Aldrich</td><td valign="top">Cat# <break/>000000011873580001</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">TRIzol</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 15596026</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">DAPI</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# 10236276001</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">SB-431542</td><td valign="top">Tocris; <xref ref-type="bibr" rid="bib30">Inman et al., 2002</xref>: <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/12065756">12065756</ext-link></td><td valign="top">Cat# 1614</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">MG-132</td><td valign="top">Tocris</td><td valign="top">Cat# 1748</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FIJI (ImageJ)</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://imagej.net/Fiji/Downloads">https://imagej.net/Fiji/Downloads</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_002285">SCR_002285</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FlowJo 10</td><td valign="top">FlowJo</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_008520">SCR_008520</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GraphPad Prism 8</td><td valign="top">GraphPad</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_002798">SCR_002798</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ASTRA6.1</td><td valign="top">Wyatt</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_001625">SCR_001625</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Octet CFR software</td><td valign="top">ForteBio</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">DLS Xia2/XDS pipeline</td><td valign="top"><xref ref-type="bibr" rid="bib84">Winter, 2010</xref>; <break/><xref ref-type="bibr" rid="bib33">Kabsch, 2010</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/20124692">20124692</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">CCP4 suite</td><td valign="top"><xref ref-type="bibr" rid="bib83">Winn et al., 2011</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/21460441">21460441</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_007255">SCR_007255</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Phaser</td><td valign="top"><xref ref-type="bibr" rid="bib47">McCoy et al., 2007</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/19461840">19461840</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_014219">SCR_014219</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Refmac</td><td valign="top"><xref ref-type="bibr" rid="bib52">Murshudov et al., 2011</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/21460454">21460454</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_014225">SCR_014225</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Coot</td><td valign="top"><xref ref-type="bibr" rid="bib20">Emsley et al., 2010</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/20383002">20383002</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_014222">SCR_014222</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">PHENIX Suite</td><td valign="top"><xref ref-type="bibr" rid="bib38">Liebschner et al., 2019</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/31588918">31588918</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_014224">SCR_014224</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Phenix.Refine</td><td valign="top"><xref ref-type="bibr" rid="bib1">Afonine et al., 2012</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/22505256">22505256</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_016736">SCR_016736</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">RSEM-1.3.0/STAR-2.5.2</td><td valign="top"><xref ref-type="bibr" rid="bib37">Li and Dewey, 2011</xref>; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/21816040">21816040</ext-link> <break/><xref ref-type="bibr" rid="bib17">Dobin et al., 2013</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/23104886">23104886</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_013027">SCR_013027</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">DESeq2 package <break/>(version 1.24.0)</td><td valign="top"><xref ref-type="bibr" rid="bib41">Love et al., 2014</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/25516281">25516281</ext-link></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:SCR_015687">SCR_015687</ext-link></td><td valign="top"/></tr></tbody></table></table-wrap></boxed-text></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63545.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewing Editor</role><aff><institution>University of Massachusetts Medical School</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Lambright</surname><given-names>David</given-names> </name><role>Reviewer</role><aff><institution>University of Massachusetts Medical School</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Shprintzen-Goldberg syndrome (SGS) is a multi-systemic connective tissue disorder, with considerable clinical overlap with Marfan and Loeys-Dietz syndromes. These syndromes have commonly been associated with enhanced TGF-β signaling. However, new data from the Hill laboratory reveal that SGS is associated with an attenuation of TGF-β-induced transcriptional responses (not an enhancement) and provide insight into the molecular mechanism. This work has important implications for the treatment of Marfan-related syndromes.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Mutations in SKI in Shprintzen-Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Philip Cole as the Senior Editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>Summary:</p><p>This is an interesting manuscript that demonstrates that SGS-associated mutations in the transcriptional repressor Ski prevent TGFb-induced degradation of Ski. This Ski stabilization is associated with suppression of binding to SMAD2/3 while maintaining repression through an interaction with SMAD4. The conclusions of this study serve to extend established knowledge of SGS-associated Ski mutations and clarify several conflicting/controversial observations related to Marfan-related syndromes more broadly.</p><p>In general, this is a strong study and presents good biochemical data using cells with CRISPR-mediated knock-in alleles to mimic SGS-associated Ski mutations as well as patient-derived cell lines. No major criticisms of the study were noted by the reviewers with the exception of a question concerning the structural analysis (Figure 5).</p><p>Essential revisions:</p><p>1) The crystal structure presented shows an N-terminal Ski peptide in a complex with SMAD2. It is unclear what new information this structure presents since a structure of Ski in complex with Smad2 has previously been reported (Mizazono et al., 2018). The authors should state what conclusions are drawn based on the new data that were not previously based on the Mizazono et al. analysis. It is not obvious that the new structure presented provides new information – if it does, this should be explicitly stated. The presentation and analysis of the structure in the Results and Discussion section of the manuscript should appropriately refer to Mizazono et al. At present, Mizazono et al. is only obliquely cited in the Discussion section of the manuscript.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63545.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The crystal structure presented shows an N-terminal Ski peptide in a complex with SMAD2. It is unclear what new information this structure presents since a structure of Ski in complex with Smad2 has previously been reported (Mizazono et al., 2018). The authors should state what conclusions are drawn based on the new data that were not previously based on the Mizazono et al. analysis. It is not obvious that the new structure presented provides new information – if it does, this should be explicitly stated. The presentation and analysis of the structure in the Results and Discussion section of the manuscript should appropriately refer to Mizazono et al. At present, Mizazono et al. is only obliquely cited in the Discussion section of the manuscript.</p></disp-quote><p>We apologize for not referring to the SMAD2–SKI structure published by Miyazono et al., in 2018, in the Results. We have now remedied this. We had actually produced our structure before the publication by Miyazono et al. We think it is very important to publish our structure in this paper, as to our knowledge it is the first SMAD structure to use eukaryotic-cell produced SMAD protein that has been phosphorylated in vivo by co-expression of the kinase domain of the relevant receptor (TGFBR1 in this case). This contrasts with the Miyazono structure that used <italic>E. coli</italic> produced pseudo-phosphorylated SMAD2 MH2 domain (where glutamic acids are used to mimic phosphates). In addition, our SKI peptide was not tagged, whereas the peptide used for the Miyazono structure has an acidic C-terminal tag. The main features of the structure are similar. This has now been clarified in the Results. We have also referenced the Miyazono paper in the Discussion.</p><p>Another advantage of our structure of the phosphorylated SMAD2 MH2 domain is that we have been able to use it to understand why SKI and SKIL only bind to phosphorylated SMAD2 and not to monomeric SMAD2. This issue was not addressed in Miyazono et al., 2018. This too has been clarified in the Results.</p></body></sub-article></article>